



Government **B**ioscience **G**rants

UPDATED MONTHLY

May 11, 2021

—  
THE ESSENTIAL GUIDE TO

# Non-Dilutive Government Funding

PUBLISHED BY



## Questions?

Liz Powell, Esq., MPH  
lpowell@G2Gconsulting.com

 [www.G2Gconsulting.com](http://www.G2Gconsulting.com)

 @G2Gconsulting





[www.G2Gconsulting.com/bioscience-corner](http://www.G2Gconsulting.com/bioscience-corner)

## GBG Report Updated Monthly

May 11, 2021

**May 21, 2021 from 10:00am-10:30 am EDT** – Join us for G2G’s Monthly [GBG Report and Highlights Call & Screen Share](#) when we will take a closer look at funding opportunities listed below and close with Q&A. Click [here](#) to register.

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			<b>ANESTHESIA (1)</b>			
1.	SmartTots (Strategies for Mitigating Anesthesia-Related neuroToxicity in Tots)Public-Private Partnership (PPP) under PASI (Pediatric Anesthesia Safety Initiative) (U01) Clinical Trials Not Allowed (NIH)	RFA-FD-21-025	<p>The overall objectives of this funding opportunity are to develop and maintain an administrative and scientific infrastructure to support the creation and execution of a series of projects under the auspices of PASI, to complement the goals of FDA to advance and inform regulatory policies and processes, and ultimately to advance public health. The SmartTots PPP funded through this announcement will be expected to perform activities such as, but not limited to:</p> <ol style="list-style-type: none"> <li>1. Maintaining and further developing the scientific and administrative infrastructure of the SmartTots PPP to support a series of projects under the PASI.</li> <li>2. Developing plans for the conduct of identified research projects, as agreed to by the FDA.</li> <li>3. Identifying, securing, and/or building, and effectively leveraging other resources, including but not limited to financial resources, for the identified projects; and upon completion of a given project, generating project results and recommendations and proposing related studies/projects</li> </ol>	Proposal Due: 5/24/21	Up to \$450,000, for 1 year	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-21-025.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-21-025.html#_Section II. Award 1</a>

<b>ANIMAL RESEARCH (2)</b>						
2.	Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R41/R42/R43/R44 Clinical Trial Not Allowed) (NIH)	PAR-21-225; 226	These FOAs encourage applications from small business concerns (SBCs) for SBIR/STTR projects to facilitate the design, creation, and implementation of novel tools and devices for the health and management of research animals, and to advance equipment that improves the operation and environmental conditions of animal facilities that support biomedical and bio-behavioral research. These efforts are important for a broad class of animal models, including but not limited to widely used model organisms such as fruit fly, worm, mouse, rat, zebrafish, frog, rabbit, swine, and nonhuman primates amongst others. These FOAs apply to invertebrate and vertebrate animals.	Proposal Due: 9/5/21	Up to \$259,613 for up to 6 months (Phase I) & Up to \$1.7 million for up to 2 years (Phase II)	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-225.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-21-225.html#_Section_II_Award_1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-226.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-21-226.html#_Section_II_Award_1</a>
<b>ARTIFICIAL INTELLIGENCE (5)</b>						
3.	Pre-Announcement Data Generation Projects of the NIH Bridge to Artificial Intelligence (Bridge2AI) Program (OT2) & Bridge2AI Integration, Dissemination, and Evaluation Center (NIH)	NOT-RM-21-022; 021	NIH plans to publish a FOA as part of the Bridge to Artificial Intelligence (Bridge2AI) Program to solicit data generation projects to produce flagship datasets for use in biomedical and behavioral science discoveries driven by applications of artificial intelligence and machine learning (AI/ML). The data generation projects will encompass expertise to incorporate into the datasets ethical principles, associated standards and tools, and skills and workforce development to address biomedical and behavioral grand challenges (see illustrative list below). A companion FOA will solicit applications for an Integration, Dissemination and Evaluation (BRIDGE) Center that will integrate, datasets and cross-cutting products across Bridge2AI Data Generation Projects, and will develop best-practices for the use of AI/ML methods in biomedical and behavioral research. It is expected that all Data Generation Projects will work collaboratively with the BRIDGE Center to achieve the goals of the Bridge2AI program.	Estimated Post Date: 6/11/21  Estimated Proposal Due Date: 8/20/21	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=333301">https://www.grants.gov/web/grants/view-opportunity.html?opId=333301</a>  <a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=333328">https://www.grants.gov/web/grants/view-opportunity.html?opId=333328</a>
4.	Program on Fairness in Artificial Intelligence in Collaboration with Amazon (FAI) (NSF)	21-585	NSF and Amazon are partnering to jointly support computational research focused on fairness in AI, with the goal of contributing to trustworthy AI systems that are readily accepted and deployed to tackle grand challenges facing society. Specific topics of interest include, but are not limited to transparency, accountability, inclusivity, potential adverse biases and effects, mitigation strategies, algorithmic advances, fairness objectives, validation of fairness, participatory design, and advances in broad accessibility and utility. Funded projects will enable broadened acceptance of AI systems, helping the U.S. to further capitalize on the potential of AI technologies.	Proposal Due: 8/3/21	Up to \$1 million, for up to 3 years	<a href="https://www.nsf.gov/pubs/2021/nsf21585/nsf21585.htm#award_info">https://www.nsf.gov/pubs/2021/nsf21585/nsf21585.htm#award_info</a>

5.	Notice of Special Interest (NOSI): Administrative Supplements to Support Collaborations to Improve the AI/ML-Readiness of NIH-Supported Data (NIH)	NOT-OD-21-094  PA-20-272	<b>ARTIFICIAL INTELLIGENCE</b>  This Notice announces the availability of supplements to active grants which are intended to support collaborations that bring together expertise in biomedicine, data management, and artificial intelligence and machine learning (AI/ML) to make NIH-supported data useful and usable for AI/ML analytics. This initiative is aligned with the <a href="#">NIH Strategic Plan for Data Science</a> , which describes actions aimed at modernizing the biomedical research data ecosystem and making data FAIR (Findable, Accessible, Interoperable, and Reusable) with high impact for open science. For the purposes of this Notice, AI/ML is inclusive of machine learning (ML), deep learning (DL), and neural networks (NN). Use FOA PA-20-272 to apply to this NOSI.	Proposal Due: 5/26/21	Up to \$200,000, for 1 year	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-094.html">https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-094.html</a>  <a href="https://grants.nih.gov/grants/guide/notice-files/PA-20-272.html#SectionII.Award1">https://grants.nih.gov/grants/guide/notice-files/PA-20-272.html# Section II. Award 1</a>
			<b>AUTOIMMUNE DISEASES (4)</b>			
6.	FY21 Lupus Research Program (LRP) (DoD/CDMRP)	W81XWH-21-LRP-IA; IPA; TVA	Three awards are expected to be funded. They include: 1) Idea Award: Supports innovative, high-risk/high-reward research that could ultimately lead to a critical discovery or major advancement, 2) Impact Award: supports high-risk/high-reward research, which if successfully addressed, has the potential to make a major impact in lupus research and 3) Transformative Vision Award: Supports research that will have an intervention at the individual and/or healthcare system level, which will result in near-term impact on the health-related quality of life of persons with lupus.	Pre-Application Due: 8/24/21  Proposal Due: 9/22/21	Up to \$2.5 million, for up to 4 years  Dependent upon award mechanism	<a href="https://cdmrp.army.mil/funding/pa/FY21-LRP-IA.pdf">https://cdmrp.army.mil/funding/pa/FY21-LRP-IA.pdf</a>  <a href="https://cdmrp.army.mil/funding/pa/FY21-LRP-IPA.pdf">https://cdmrp.army.mil/funding/pa/FY21-LRP-IPA.pdf</a>  <a href="https://cdmrp.army.mil/funding/pa/FY21-LRP-TVA.pdf">https://cdmrp.army.mil/funding/pa/FY21-LRP-TVA.pdf</a>
7.	National Lupus Outreach and Clinical Trial Education Program (HHS/OASH)	MP-CPI-21-005	The Lupus Program seeks to demonstrate the effectiveness of interventions for increasing minority participation in lupus-related clinical trials to help to reduce lupus-related health disparities experienced by racial and ethnic minority populations. Studies have indicated that Blacks, Asians, Pacific Islanders, and Hispanics experience higher rates of diagnosis of system lupus erythematosus (SLE) and more severe symptoms and complications than whites. Projects will seek to develop public-private and community partnerships to support and/or sustain effective practices to increase racial and ethnic minority enrollment and retention in lupus clinical trials, and tailor existing outreach or education interventions that focus on health care providers/practitioners and/or racial and ethnic minority populations.	Proposal Due: 6/29/21	Up to \$500,000 per year, for up to 2 years	<a href="https://www.grantsolutions.gov/gs/previewPublicAnnouncement.do?id=91751">https://www.grantsolutions.gov/gs/previewPublicAnnouncement.do?id=91751</a>

<b>BIOMEDICAL DATA MANAGEMENT (1)</b>						
8.	Considerations, Options, and Resources for Data Management in PHS Funded Research (HHS/OASH)	IR-ORI-21-001	The goal of this funding opportunity is to support the development of approaches and resources for data management and stewardship (which also includes data storage and retention of an array of data types) that will help enhance the integrity and reliability of data generated with Public Health Service (PHS) funds, ensure data acquired using PHS funds are available for subsequent use by the research community, and ensure data are available for examination should there be an issue related to the integrity, authenticity, reproducibility, and/or reliability of the research.	Proposal Due: 6/30/21	Up to \$600,000, for up to 2 years	<a href="https://www.grantsolutions.gov/gs/previewPublicAnnouncement.do?id=92601">https://www.grantsolutions.gov/gs/previewPublicAnnouncement.do?id=92601</a>
<b>BIRTH DEFECTS (1)</b>						
9.	Developmental Mechanisms of Human Structural Birth Defects (P01 Clinical Trial Not Allowed) (NIH)	RFA-HD-22-004	The purpose of this FOA is to support innovative, multidisciplinary, interactive, and synergistic program projects that integrate basic, translational, and clinical approaches to understanding the developmental biology and genetic basis of significant congenital human malformations. Each program project will consist of three component research projects, in addition to associated cores. At least one project must use basic research in an animal model system and at least one project must be clinical or translational in nature. The component research projects must share a common central theme, focus, or objective on a specific major developmental defect or malformation that is genotypically, mechanistically, biologically, or phenotypically analogous or homologous in both animal models and humans.	Letter of Intent Due: 6/29/21  Proposal Due: 7/29/21	Up to \$1 million per year, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-22-004.html#_SectionII.Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-22-004.html#_SectionII.Award_1</a>
<b>BONE MARROW FAILURE (2)</b>						
10.	FY21 Bone Marrow Failure Research Program (BMFRP) (DoD/CDMRP)	W81XWH-21-BMFRP-IDA; IIRA	The objective of the BMFRP is to fund scientifically meritorious research focused on BMF diseases. Investigator-initiated research is encouraged in the areas of congenital or acquired BMF. Studies focused on BMF syndromes and their progression to other malignancies, such as leukemia, are acceptable. However, research primarily focused on myeloproliferative neoplasms, leukemia, or other malignancies is discouraged. Two awards are expected to be funded. They include the 1) Idea Development Award: Supports innovative ideas and high-impact approaches based on scientifically sound evidence to move toward the vision to understand and cure BMF and 2) Investigator-Initiated Research Award (IIRA): supports studies that further develop ideas, expand upon key discoveries, and have the potential to make significant advances in research, patient care.	Pre-Application Due: 7/9/21  Proposal Due: 10/12/21	Up to \$800,000, for up to 4 years  Dependent upon award mechanism	<a href="https://cdmrp.army.mil/funding/pa/FY21-BMFRP-IDA.pdf">https://cdmrp.army.mil/funding/pa/FY21-BMFRP-IDA.pdf</a>  <a href="https://cdmrp.army.mil/funding/pa/FY21-BMFRP-IIRA.pdf">https://cdmrp.army.mil/funding/pa/FY21-BMFRP-IIRA.pdf</a>

<b>BROAD AGENCY ANNOUNCEMENTS (29)</b>						
11.	BARDA Broad Agency Announcement (HHS/BARDA)	BAA-18-100-SOL-00003	<p>Due to the COVID-19 response, any white papers or full proposals submissions, other than those that are in support of COVID-19, will be put into a queue. Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interest. COVID-19 response related Areas of Interest includes:</p> <ul style="list-style-type: none"> <li>• Diagnostic assay for coronavirus using FDA-cleared platforms</li> <li>• Point-of-care diagnostic assay for detection of SARS-CoV-2 virus</li> <li>• Diagnostic assay for detection of COVID-19 disease</li> <li>• Diagnostic Assay for SARS-CoV-2 as part of FDA-cleared panel for influenza and other respiratory viruses using FDA-cleared platforms</li> <li>• COVID-19 Therapeutics</li> <li>• AOI 17 Advanced Manufacturing Technologies</li> </ul>	White Papers Due: 10/31/21	Dependent upon proposal	<p><a href="https://beta.sam.gov/opp/30f25542d42b4e8aaefb69adfc4ac8dd/view">https://beta.sam.gov/opp/30f25542d42b4e8aaefb69adfc4ac8dd/view</a></p> <p><a href="https://www.mediccountermeasures.gov/barda/barda-baa">https://www.mediccountermeasures.gov/barda/barda-baa</a></p>
12.	BARDA's Division of Research, Innovation & Ventures (DRIVE) Easy Broad Agency Announcement (EZ-BAA) (HHS/BARDA)	BAA-20-100-SOL-0002	<p>BARDA is accepting submissions through the EZ-BAA for the following areas of interest (AOIs): AOI#1: Early Notification to Act, Control and Treat: seeking technologies to identify, characterize, and broadly adapt biological, biometric, behavioral and physiological signatures that can signal health security threat infections or exposures prior to symptoms. AOI#2: Infection Severity &amp; Solving Sepsis: catalyzing technologies along the sepsis patient continuum to empower the patients, providers with a focus on technologies that address sepsis. AOI#5: Repurposing Drugs In Response to Chemical Threats: repurpose common therapeutics as medical counter measures and treat the symptoms associated with chemical agent exposure. AOI#6: Beyond the Needle: The goal of this program is to develop alternative vaccine technologies to make vaccinations easier to administer and more widely available. The goal is to reduce the burden of traditional vaccine delivery via needle and syringe on the healthcare system and supply-chain.</p>	No Due Dates, open until 2/3/23	Up to \$750,000, per award	<p><a href="https://beta.sam.gov/opp/f2b87e34fecf47d0a48e9b03e8e826ff/view">https://beta.sam.gov/opp/f2b87e34fecf47d0a48e9b03e8e826ff/view</a></p> <p><a href="https://drive.hhs.gov/partner.html">https://drive.hhs.gov/partner.html</a></p>

13.	USAMRDC Broad Agency Announcement for Extramural Medical Research (DoD)	W81XW H18SBA A1	<p style="text-align: center;"><b>BROAD AGENCY ANNOUNCEMENTS</b></p> <p>This BAA supports extramural R&amp;D ideas for basic and applied research to support scientific study and experimentation directed toward advancing the state of the art or increasing knowledge or understanding rather than focusing on development of a specific system or hardware solution. R&amp;D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease Research Program; Combat Casualty Care Research Program; Military Operational Research Program; Clinical and Rehabilitative Medicine Research Program; Medical Biological Defense Research Program; Medical Chemical Defense Research Program; Medical Simulation and Information Sciences Research Program.</p>	<p>No Due Dates, open until 9/30/22</p> <p>Pre-application Required</p> <p>Full Proposal by invitation</p>	<p>Dependent upon proposal, for up to 5 years</p>	<p><a href="https://www.grants.gov/web/grants/search-grants.html?keywords=W81XWH18SBA1">https://www.grants.gov/web/grants/search-grants.html?keywords=W81XWH18SBA1</a></p> <p>(Full Announcement in Related Documents Tab)</p>
14.	U.S. Army Research Institute for the Behavioral and Social Sciences (ARI) Broad Agency Announcement for Basic, Applied, and Advanced Research (DoD)	W911NF- 18-S- 0005	<p>Programs funded under this BAA include basic research, applied research, and advanced technology development that can improve human performance and Army readiness. Funding of R&amp;D within ARI areas of interest will be determined by funding constraints and priorities set during each budget cycle. Topic areas of basic research interest include: Understanding Team Dynamics; Improving Leadership and Leader Development; Identifying, Assessing, and Assigning Quality Personnel; Enhancing Lifelong Learning. ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology.</p>	<p>No Due Dates, open until 4/29/23</p> <p>Full Proposal Required</p>	<p>Dependent upon proposal</p>	<p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=304462">https://www.grants.gov/web/grants/view-opportunity.html?opId=304462</a></p> <p>(Full Announcement in Related Documents Tab)</p>
15.	Army Research Office Broad Agency Announcement for Fundamental Research (DoD)	W911NF- 17-S- 0002-07	<p>The purpose of this Broad Agency Announcement (BAA) is to solicit research proposals in the engineering, physical, life, and information sciences for submission to the Army Research Office (ARO) for consideration for possible funding. ARL has an overarching technical strategy to support Strategic Land Power Dominance for the Army of 2030 and beyond. The strategy is based on seven Science and Technology (S&amp;T) Core Technical Competencies: Computational Sciences, Ballistics Sciences, Materials &amp; Manufacturing Sciences, Protection Sciences, Propulsion Sciences, Network &amp; Information Sciences and Human Sciences.</p>	<p>No Due Dates, open until 3/31/22</p>	<p>Dependent upon proposal</p>	<p><a href="https://www.arl.army.mil/wp-content/uploads/2020/04/ARO-BAA-Amendment-7-Final.pdf">https://www.arl.army.mil/wp-content/uploads/2020/04/ARO-BAA-Amendment-7-Final.pdf</a></p>

16.	Army Research Office Broad Agency Announcement Staff Research Program (DoD)	W911NF-20S0003	<p style="text-align: center;"><b>BROAD AGENCY ANNOUNCEMENTS</b></p> <p>The ARO is soliciting proposals for Staff Research Program opportunities. The purpose of the program is to enable ARO scientific staff to maintain and expand professional competence in support of fulfilling the ARO mission through the conduct of hands-on, basic research. The staff research will be performed collaboratively with institutions external to ARO. Staff research efforts will involve scientific study directed toward advancing the state-of-the-art or increasing knowledge and scientific understanding in engineering, physical, life and information sciences, when there is an intersection with the interests and capabilities of the participating external institutions in these basic research areas.</p>	No Due Dates, open until 2/19/25	Dependent upon proposal	<a href="https://www.arl.army.mil/wp-content/uploads/2020/04/arl-baa-Staff-Research-PA.pdf">https://www.arl.army.mil/wp-content/uploads/2020/04/arl-baa-Staff-Research-PA.pdf</a>
17.	Army Research Laboratory Broad Agency Announcement for Basic and Applied Scientific Research (DoD)	W911NF-17-S-0003	<p>The ARL BAA seeks proposals from institutions of higher education, nonprofit organizations, state and local governments, foreign organizations, foreign public entities, and for-profit organizations (i.e. large and small businesses) for research based on the following S&amp;T campaigns: Computational Sciences, Materials Research, Sciences for Maneuver, Information Sciences, Sciences for Lethality and Protection, Human Sciences, and Assessment and Analysis. Further details are described in the ARL Technical Strategy and in the ARL S&amp;T Campaigns located at <a href="http://www.arl.army.mil">www.arl.army.mil</a>. These documents are subject to periodic refinements which may result in taxonomy inconsistencies. These inconsistencies should not affect the efficacy of the BAA to present a complete portfolio of essential ARL research.</p>	No Due Dates, open until 3/31/22	Dependent upon proposal	<a href="https://www.arl.army.mil/wp-content/uploads/2019/11/arl-baa-ARL-BAA-W911NF-17-S-0003-Amendment-07-2-6-19.pdf">https://www.arl.army.mil/wp-content/uploads/2019/11/arl-baa-ARL-BAA-W911NF-17-S-0003-Amendment-07-2-6-19.pdf</a>
18.	The USAID Global Health Broad Agency Announcement for Research and Development (2018) (USAID)	GLOBAL HEALTH -BAA-2018	<p>This FOA seeks opportunities to co-create, co-design, co-invest, and collaborate in the research, development, piloting, testing, and scaling of innovative, practical and cost-effective interventions to address the most pressing problems in global health. The United States Agency for International Development (USAID) invites organizations and companies to participate with USAID, in cooperation with its partners, to generate novel tools and approaches that accelerate and sustain improved health outcomes in developing countries.</p>	<p>Expression of Interest accepted on a rolling basis though 5/30/22</p> <p>Must be invited for full proposal</p>	Dependent upon proposal and award type	<p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=305999">https://www.grants.gov/web/grants/view-opportunity.html?opId=305999</a></p> <p>(Full Announcement in Related Documents Tab)</p>

19.	Air Force Office of Scientific Research Broad Agency Announcement (DoD)	FA9550-18-S-0003	<p style="text-align: center;"><b>BROAD AGENCY ANNOUNCEMENTS</b></p> <p>This BAA's focus is on research areas that offer significant and comprehensive benefits to national warfighting and peacekeeping capabilities. These areas are organized and managed in two scientific branches: Engineering and Information Sciences (RTA) and Physical and Biological Sciences (RTB). Research topics in the Chemistry and Biological sciences categories include Biophysics; Human Performance and Biosystems; Mechanics of Multifunctional Materials and Microsystems; Molecular Dynamics and Theoretical Chemistry; Natural Materials, Systems, and Extremophiles; and Organic Materials Chemistry. For a full list of applicable research topics, see full solicitation</p>	Proposals accepted on a rolling basis	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=305996">https://www.grants.gov/web/grants/view-opportunity.html?opId=305996</a>  (Full Announcement in Related Documents Tab)
20.	Dept. of the Army, USAMRAA – BAA for Extramural Biomedical Research and Development (DoD)	W81XW H-18-S-SOC1	<p>A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel (medical devices, drugs, and biologics) for early intervention in life-threatening injuries, prolonged field care, human performance optimization, and canine medicine/performance. Special Operations Forces (SOF) medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. Equipment must be easy to use, require minimum maintenance, and have low power consumption. Drugs and biologics should not require refrigeration or special handling. All materiel and related techniques must be simple and effective, and easily modified for commercialization. Projects may apply existing knowledge for which concept and/or patient care efficacy have already been demonstrated to meet SOF requirements.</p>	<p>Submissions accepted through 7/31/23</p> <p>Submission of a pre-proposal is required</p>	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=307754">https://www.grants.gov/web/grants/view-opportunity.html?opId=307754</a>  (Full Announcement in Related Documents Tab)
21.	Army Applications Lab BAA for Disruptive Applications (DoD)	W911NF-19-S-0004	<p>AAL is interested in any and all technologies which can be shown to enable the Army of 2028 to be ready to deploy, fight, and win decisively against any adversary, anytime, and anywhere, in a joint, multi-domain, high-intensity conflict, while simultaneously deterring others and maintaining its ability to conduct irregular warfare. AAL is seeking technologies that address a wide range of Army needs consistent with CFT capability focus areas and associated programs and lines of effort as well as potentially disruptive new capabilities that augment or enhance Army capability overmatch.</p>	<p>Submissions accepted through 5/1/24</p> <p>Submission of a pre-proposal is required</p>	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=315517">https://www.grants.gov/web/grants/view-opportunity.html?opId=315517</a>  (Full Announcement in Related Documents Tab)

22.	United States Military Academy Broad Agency Announcement (DoD)	W911NF-20-S-0008	<p style="text-align: center;"><b>BROAD AGENCY ANNOUNCEMENTS</b></p> <p>The USMA BAA identifies topics of interest to the USMA departments, directorates, and research centers and institutes. These groups focus on executing in-house research programs, with a significant emphasis on collaborative research with other organizations. The groups fund a modest amount of extramural research in certain specific areas, and those areas are described in this BAA. Proposals are sought for cutting-edge innovative research that could produce discoveries with a significant impact to enable new and improved Army technologies and related operational capabilities and related technologies.</p>	Proposals accepted on a rolling basis	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=325932">https://www.grants.gov/web/grants/view-opportunity.html?opId=325932</a>  (Full Announcement in Related Documents Tab)
23.	Opportunities from the National Virtual Biotechnology Laboratory (NVBL) (DOE)	N/A	The National Virtual Biotechnology Laboratory (NVBL) is a consortium of DOE National laboratories, each with core capabilities relevant to the threats posed by COVID-19. The NVBL is taking advantage of DOE user facilities, including light and neutron sources, nanoscale science centers, sequencing and bio-characterization facilities, and high-performance computer facilities, to address key challenges in responding to the COVID-19 threat. Examples include developing innovations in testing capabilities, identifying targets for medical therapeutics, providing epidemiological and logistical support, and addressing supply chain bottlenecks.	N/A	Dependent upon solicitation and proposal	<a href="https://science.osti.gov/nvbl?utm_medium=email&amp;utm_source=FYI&amp;dm_i=1ZJN.6UU9U.RBBVZX.RI3TV.1">https://science.osti.gov/nvbl?utm_medium=email&amp;utm_source=FYI&amp;dm_i=1ZJN.6UU9U.RBBVZX.RI3TV.1</a>
24.	Broad Agency Announcement (BAA) C4ISR, Information Operations, Cyberspace Operations and Information Technology System Research (DoD)	N66001-20-S-4702	The Naval Information Warfare Center, Pacific (NIWC Pacific) is soliciting white papers and proposals for competitive selection of basic research, applied research, advanced technology development, and advanced component development and prototype (hereinafter referred to as research). Submissions in response to this announcement shall be for areas relating to the advancement of Command, Control, Communications, Computers, Intelligence, Surveillance, and Reconnaissance (C4ISR) capabilities, enabling technologies for Information Operations and Cyberspace Operations, and Information Technology systems. Accordingly, proposals selected for award are considered to be the result of full and open competition and fully compliant with PL 98-369, "The Competition in Contracting Act of 1984." This BAA is for procurement contracts (hereinafter referred to as contracts), grants, cooperative agreements, and other transactions. Proposed research should investigate unique and innovative approaches for defining and developing next generation integratable C4ISR capabilities and command suites.	White Papers Due: 6/4/21	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=327529">https://www.grants.gov/web/grants/view-opportunity.html?opId=327529</a>  (Full Announcement in Related Documents Tab)

25.	US Army Combat Capabilities Development Command Broad Agency Announcement (DoD)	W911QY 20R0022	<p align="center"><b>BROAD AGENCY ANNOUNCEMENTS</b></p> <p>Broad Agency Announcement Solicitation for the US Army Combat Capabilities Development Command - Soldier Center (CCDC-SC). Please see the BAA solicitation document for the submission instructions and areas of interest. This posting is not for a specific requirement - only to post the BAA solicitation so that interested parties can submit white papers and proposals for grants and other assistance agreements.</p>	Proposals accepted on a rolling basis	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=327285">https://www.grants.gov/web/grants/view-opportunity.html?opId=327285</a>  (Full Announcement in Related Documents Tab)
26.	Airman Readiness Medical Research (ARMR) Hybrid BAA (DoD)	FA8650-20-S-6008	The Warfighter Medical Optimization Division (RHM) intends to solicit White Papers under this announcement with the focus of conducting medical research in support of optimizing of the warfighter by enabling, enhancing, restoring, and sustaining the Airman to more effectively execute the Air Force mission. This medical research objective is dual natured: (1) ensure medical availability of Airmen by analyzing attributes (sensory, behavioral, physiologic) and operational environments (chemical, physical, psychological, biological, radiological stressors) to drive optimal performance of Airmen engaged in high-demand, high-impact mission tasks (2) investigate how the flight environment affects the process of life, the ability to maintain homeostasis, and the risk for injury or secondary insult, seeking to ameliorate these stressors to optimize Airman health and performance.	White papers accepted on rolling basis until 4/30/26	Up to \$49 million, per award	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=327332">https://www.grants.gov/web/grants/view-opportunity.html?opId=327332</a>  (Full Announcement in Related Documents Tab)
27.	Defense Sciences Office Office-wide BAA (DoD/DARPA)	HR00112 0S0048	The mission of the Defense Advanced Research Projects Agency (DARPA) Defense Sciences Office (DSO) is to identify and create the next generation of scientific discovery by pursuing high-risk, high-payoff research initiatives across a broad spectrum of science and engineering disciplines and transforming these initiatives into disruptive technologies for U.S. national security.	Proposals accepted on a rolling basis until 6/11/21	Dependent upon proposal	<a href="https://beta.sam.gov/opp/36d6bc789b364142a0f7a267017b06d9/view">https://beta.sam.gov/opp/36d6bc789b364142a0f7a267017b06d9/view</a>
28.	Transforming the Battlespace BAA (DoD/DARPA)	HR00112 0S0053	The Tactical Technology Office (TTO) of DARPA is soliciting executive summaries, proposal abstracts and proposals for applied research, advanced technology development, and platform demonstrations that aim to enable disruptive capabilities for future warfare. TTO projects usually define a reference operational system upfront, decompose critical technical risks, and define a demonstration around them. Use of off-the-shelf technology for lower risk subsystems reduces program cost and schedule but allows critical technologies to be matured and demonstrated.	Proposals accepted on a rolling basis until 6/11/21	Dependent upon proposal	<a href="https://beta.sam.gov/opp/03eeb369da1c4c0ea55ff4d1baed15af/view">https://beta.sam.gov/opp/03eeb369da1c4c0ea55ff4d1baed15af/view</a>

29.	Research for the Department of Health and Human Services under Contracts, Other Transaction Agreements, & Technology Investment Agreements for Treatment and Protection from COVID-19 (HHS/OWS)	OWS-BAA-20-01	<p style="text-align: center;"><b>BROAD AGENCY ANNOUNCEMENTS</b></p> <p>This BAA contemplates the award of procurement Contracts, TIAs, and OTAs in support of the mission areas to foster and/or conduct the development of FDA- approved medical products in support of Operation Warp Speed (OWS). OWS is a partnership among components of the Department of Health and Human Services (HHS), including the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), and the Department of Defense (DoD) to coordinate existing HHS-wide efforts, including the NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership, NIH’s Rapid Acceleration of Diagnostics (RADx) initiative, and work by BARDA. As the purpose of this BAA is to identify the best available science in the identified areas of research interest.</p>	Proposals accepted on a rolling basis	Dependent upon proposal	<a href="https://beta.sam.gov/opp/d3b19cfbad31430dab3880812ce2abf3/view">https://beta.sam.gov/opp/d3b19cfbad31430dab3880812ce2abf3/view</a>
30.	FY2021 Long Range Broad Agency Announcement (BAA) for Navy and Marine Corps Science and Technology (DoD/ONR)	N00014-21-S-B001	The Office of Naval Research (ONR), ONR Global, and Marine Corps Warfighting Lab (MCWL) are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. Readers should note that this is an announcement to declare ONR, ONRG and MCWLs broad role in competitive funding of meritorious research across a spectrum of science and engineering disciplines.	Proposals accepted on a rolling basis until 10/30/21	Dependent upon proposal	<a href="https://www.onr.navy.mil/en/work-with-us/funding-opportunities/announcements">https://www.onr.navy.mil/en/work-with-us/funding-opportunities/announcements</a>
31.	Information Innovation Office (I2O) Office-wide (DoD/DARPA)	HR001121S0010	This BAA seeks revolutionary research ideas for topics not being addressed by ongoing I2O programs or other published solicitations. Potential proposers are encouraged to review the current I2O programs ( <a href="http://www.darpa.mil/about-us/offices/i2o">http://www.darpa.mil/about-us/offices/i2o</a> ) and solicitations ( <a href="http://www.darpa.mil/work-with-us/opportunities">http://www.darpa.mil/work-with-us/opportunities</a> ) to avoid proposing efforts that duplicate existing activities or that are responsive to other published I2O solicitations. I2O programs are organized into four thrust areas: Proficient artificial intelligence (AI), Advantage in cyber operations, Confidence in the information domain & Resilient, adaptable, and secure systems.	Abstract Due: 9/23/21  Proposal Due: 10/28/21	Dependent upon proposal	<a href="https://beta.sam.gov/opp/b67c8910977b46f9828101812bb38617/view">https://beta.sam.gov/opp/b67c8910977b46f9828101812bb38617/view</a>

32.	Broad Agency Announcement (BAA) Science & Technology for Advanced Manufacturing Projects (STAMP) (DoD/ONR)	N00014-21-S-B002	<p style="text-align: center;"><b>BROAD AGENCY ANNOUNCEMENTS</b></p> <p>The Manufacturing Technology Program (ManTech) is the Defense Department’s investment mechanism for staying at the forefront of defense-essential manufacturing capability. The ManTech Program targets the needs of our warfighters and weapon system programs by helping to find and implement affordable low-risk solutions. The focus of this BAA is primarily on projects that continue to advance the systems engineering approach needed for the design, fabrication, and manufacture of structural components to address challenges in system weight, performance, affordability, and/or survivability. The intent is to bring together materials designers, materials suppliers, product designers, and manufacturers to collaborate on the design, production, and commercialization of novel affordable, manufacturable systems.</p>	Proposals accepted on a rolling basis until 10/30/21	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=329699">https://www.grants.gov/web/grants/view-opportunity.html?opId=329699</a>  (Full Announcement in Related Documents Tab)
33.	Pre-Announcement SARS-CoV-2 (COVID-19) Program Activities Broad Agency Announcement (BAA) (HHS/OASH)	OS-PAW-20-001	<p>The Office of the Assistant Secretary for Health (OASH) established the Laboratory and Diagnostics Working Group (LDWG) seeking submissions to a BAA “to prevent, prepare for, and respond to coronavirus, for expenses to research, develop, validate, manufacture, purchase, administer, and expand capacity for COVID–19 tests to effectively monitor and suppress COVID–19” When posted, this FOA will guide the submission of white papers, which may be followed by full proposal submissions for funding consideration. Applicants will have the option of forgoing the white paper submission for direct submission of a full proposals. Applications will be accepted and reviewed on a rolling basis to address public needs.</p>	Estimated Post Date: Spring 2021	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328065">https://www.grants.gov/web/grants/view-opportunity.html?opId=328065</a>
34.	Research Interests of the United States Air Force Academy (DoD)	USAFA-BAA-2021	<p>USAFA’s Dean of Faculty Research Office is announcing to business and academia the intent to solicit white papers/proposals for USAFA research efforts through this BAA. USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. Research would essentially reveal mechanisms of existing natural systems, methods to incorporate present biological materials in nature, or disclose new capabilities within existing systems and/or materials.</p>	Proposals accepted on a rolling basis	Dependent upon proposal, for up to 5 years	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=330175">https://www.grants.gov/web/grants/view-opportunity.html?opId=330175</a>  (Full Announcement in Related Documents Tab)

35.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic Scientific Research, Foundational Science Research Unit (2021-2022) (DoD)	W911NF-21-S-0007	<p style="text-align: center;"><b>BROAD AGENCY ANNOUNCEMENTS</b></p> <p>The U.S. Army Research Institute for the Behavioral and Social Sciences is the Army's lead agency for the conduct of research, development, and analyses for the improvement of Army readiness and performance via research advances and applications of the behavioral and social sciences that address personnel, organization, training, and leader development issues. Programs funded under this BAA include basic research that can improve human performance and Army readiness. Domains of interest include 1) Personnel Testing &amp; Performance, 2) Learning in Formal and Informal Environments, 3) Organizational Effectiveness and 4) Leader Processes and Measurement.</p>	<p>White Papers Accepted Until: 5/15/22</p> <p>Proposals Accepted Until: 8/4/22</p>	<p>Dependent upon proposal</p>	<p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=331391">https://www.grants.gov/web/grants/view-opportunity.html?opId=331391</a></p> <p>(Full Announcement in Related Documents Tab)</p>
36.	2021 NIAID Omnibus Broad Agency Announcement HHS-NIH-NIAID-BAA2021-1 (NIH)	NOT-AI-21-045	<p>Offers submitted in response to this BAA will be required to present separate detailed technical and business proposals designed to meet the Technical Objectives described for each Research Area proposed. The Research Areas included in BAA are as follows:</p> <p><u>Research Area 001</u>: Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases. The objective of Research Area 001 is to advance vaccine technologies and platforms that have sufficient proof of concept data and/or clinical data to support vaccine development through manufacturing, toxicology testing, and testing in phase 1 or 2 clinical trials.</p> <p><u>Research Area 002</u>: Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases.</p>	<p>Proposal Due: 5/24/21</p>	<p>Up to \$4 million for up to 5 year</p> <p>Dependent upon award mechanism</p>	<p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AI-21-045.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AI-21-045.html</a></p>
37.	Next New & Emerging QUBIT Science & Technology (nextNEQST) (DoD/ARO)	W911NF 21S0010	<p>The U.S. Army Research Office (ARO) in collaboration with the Laboratory for Physical Sciences (LPS) is soliciting proposals for research in the next New and Emerging Qubit Science and Technology (nextNEQST) program. nextNEQST focuses on qubit systems that explore new operating regimes and environments, fundamentally new methods of fabrication, and new methods of design, control, or operation. These explorations should have in mind the development of quantum computation where the novel properties of these systems create significant advantages in coherence, fabrication, and/or qubit operation over current state-of-the-art qubits.</p>	<p>White Paper Due: 5/18/21</p> <p>Proposal Due: 7/20/21</p>	<p>Up to \$499,999, for up to 4 years</p>	<p><a href="https://www.arl.army.mil/wp-content/uploads/2021/04/NEQST-BAA-Final-V3.pdf">https://www.arl.army.mil/wp-content/uploads/2021/04/NEQST-BAA-Final-V3.pdf</a></p>

38.	Biological Technologies BAA (DoD/DARPA)	HR00112 1S0025	<p align="center"><b>BROAD AGENCY ANNOUNCEMENTS</b></p> <p>BTO's research investment portfolio includes combating pandemic disease, innovative physiological interventions, human performance and warfighter readiness, and deep exploration of changing ecologies and environments for improving U.S. capabilities and resilience. BTO's programs operate across a wide range of scales, from individual cells to the warfighter to global ecosystems. BTO responds to the urgent and long-term needs of the DoD and addresses national security priorities. BTO is interested in submissions related to the following topic areas: Human Performance, Materials, Sensors, Processing, Biosecurity, Biodefense</p>	Abstracts & Proposals accepted on a Rolling Basis until 4/22/22	Dependent upon proposal	<a href="https://beta.sam.gov/opp/df93a5637fc419a8ea392ee949f9c79/view">https://beta.sam.gov/opp/df93a5637fc419a8ea392ee949f9c79/view</a>
39.	Special Announcement for 2021 Office of Naval Research Global Research Opportunity: Global-X Challenge (DoD/ONR)	N00014-21-S-SN10	ONR Global is interested in promising concepts to achieve revolutionary capability advances with both military and commercial value in the multidisciplinary technology challenge areas described below. This Global-X Challenge provides an opportunity for these international researchers to collaborate, generate revolutionary ideas and demonstrate these ideas will succeed. ONR Global invites outstanding international researchers to form multi-national, multidisciplinary teams to address one or more of these capability challenges.	White Paper Due: 5/28/21  Proposal Due: 7/9/21	Up to \$1 million, for up to 18 months	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=333307">https://www.grants.gov/web/grants/view-opportunity.html?opId=333307</a>  (Full Announcement in Related Documents Tab)
			<b>BURN INJURY (2)</b>			
40.	FY2 Military Burn Research Program (MBRP) (DoD/ CDMRP)	W81XW H-21-MBRP-CTRA; IDA	Two awards are available under the FY 21 MBRP: The Clinical Translational Research Award (CTRA) and Idea Development Award (IDA). The CTRA is intended to support human research projects that are likely to have a major impact on patient care by applying promising and well-founded research findings to the care of the burn-injured patient, particularly at the point-of-injury, or during the acute phase of injury. Impact is a key component of this award mechanism. The potential impact of the research, both short-term and long-term, in addressing the FY21 MBRP Focus Area should be clearly described. High-impact research will, if successful, significantly advance the burn research field and the care of burn-injured patients. The IDA supports new ideas that represent innovative approaches to military-relevant burn research and have the potential to make an important contribution to the MBRP mission. Research deemed innovative may represent a new paradigm, challenge current paradigms, or look at existing problems from new perspectives.	Pre-Application Due: 6/8/21  Full Proposal Due: 9/30/21	Up to \$1.5 million, for up to 4 years  Dependent upon award mechanism	<a href="https://cdmrp.army.mil/funding/pa/FY21-MBRP-IDA.pdf">https://cdmrp.army.mil/funding/pa/FY21-MBRP-IDA.pdf</a>  <a href="https://cdmrp.army.mil/funding/pa/FY21-MBRP-CTRA.pdf">https://cdmrp.army.mil/funding/pa/FY21-MBRP-CTRA.pdf</a>

CANCER (44)						
41.	FY21 Melanoma Research Program (MRP) (DoD/CDMRP)	W81XW H-21-MRP-IA; MCAA; TSA; TRA; MALA; MASA;	Seven awards are funded under the FY21 MRP. They are: (1) Idea Award: Supports high-risk/high-gain approaches to melanoma research (2) Mid-Career Accelerator Award: supports mid-career researchers, (3) Team Science Award: supports partnerships between independent investigators (4) Translational Research Award: supports studies leveraging existing biobanks, biorepositories, or clinical trials, (5) Translational Research Award (Collaborator Option—supports investigators in a joint study aiming to leverage existing biobanks, biorepositories, ongoing or completed clinical trial, 6) Melanoma Academy Leadership Award: supports individuals who are established melanoma researchers and 7) Melanoma Academy Scholar Award: supports mentoring, national networking, collaborations.	Pre-Application Due: 6/29/21 8/4/21  Proposal Due: 8/26/21 9/28/21	Up to \$1.3 million, for up to 4 years  Dependent upon award mechanism	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=333426">https://www.grants.gov/web/grants/view-opportunity.html?opId=333426</a>  <a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=333425">https://www.grants.gov/web/grants/view-opportunity.html?opId=333425</a>  <a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=333429">https://www.grants.gov/web/grants/view-opportunity.html?opId=333429</a>  <a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=333428">https://www.grants.gov/web/grants/view-opportunity.html?opId=333428</a>  <a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=333416">https://www.grants.gov/web/grants/view-opportunity.html?opId=333416</a>  <a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=333427">https://www.grants.gov/web/grants/view-opportunity.html?opId=333427</a>

42.	FY21 Kidney Cancer Research Program (KCRP) (DoD/CDMRP)	W81XW H-21-KCRP-CA; IDA; PCFA; TRPA	<p style="text-align: center;"><b>CANCER</b></p> <p>KCRP encompasses four awards for FY21. They are: 1) Concept award: supports highly innovative, untested, potentially groundbreaking novel concepts in kidney cancer, 2) Idea Development Award: intended to support innovative ideas and high- impact approaches, based on scientifically sound evidence, to move toward the KCRP vision of eliminating kidney cancer, 3) Postdoctoral and Clinical Fellowship Award: supports recent doctoral or medical school graduates in pursuit of innovative, high-impact kidney cancer research during their postdoctoral and/or clinical fellowship and allows them to obtain the necessary experience for an independent career as a leader in kidney cancer research &amp; 4) Translational Research Partnership Award: supports partnerships between clinicians and research scientists that will accelerate the movement of promising ideas in kidney cancer toward clinical applications.</p>	<p>Letter of Intent Due: 6/15/21 6/22/21</p> <p>Proposal Due: 7/13/21 10/5/21</p>	<p>Up to \$2 million, for up to 4 years</p> <p>Dependent upon award mechanism</p>	<p><a href="https://cdmrp.army.mil/funding/pa/FY21-KCRP-CA.pdf">https://cdmrp.army.mil/funding/pa/FY21-KCRP-CA.pdf</a></p> <p><a href="https://cdmrp.army.mil/funding/pa/FY21-KCRP-IDA.pdf">https://cdmrp.army.mil/funding/pa/FY21-KCRP-IDA.pdf</a></p> <p><a href="https://cdmrp.army.mil/funding/pa/FY21-KCRP-PCFA.pdf">https://cdmrp.army.mil/funding/pa/FY21-KCRP-PCFA.pdf</a></p> <p><a href="https://cdmrp.army.mil/funding/pa/FY21-KCRP-TRPA.pdf">https://cdmrp.army.mil/funding/pa/FY21-KCRP-TRPA.pdf</a></p>
43.	Notice of Special Interest (NOSI): Administrative Supplements to Stimulate and Strengthen Global Cancer Survivorship Research (NIH)	NOT-CA-21-058  PA-20-272	This NOSI announces an opportunity for supplemental funding to active, eligible NCI-funded grants and cooperative agreements to support global cancer survivorship research. These administrative supplements are intended to support NCI-funded investigators to leverage existing relationships/partnerships with stakeholders in low- and middle-income countries (LMICs) to conduct research that will enhance understanding of the gaps in post-treatment follow-up care, with the goal of addressing physical and psychosocial needs of cancer survivors and their caregivers at the individual, facility, and systems levels. Use FOA 20-272 to apply.	Proposal Due: 6/11/21	Up to \$125,000, for up to 1 year	<p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-058.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-058.html</a></p> <p><a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-272.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-272.html#_Section II. Award 1</a></p>
44.	Pre-Announcement for Translational and Basic Science Research in & Coordinating and Data Management Center for Early Lesions (TBEL) (NIH)	NOT-CA-21-060; 61	FOA 21-060 calls for applications for Translational and Basic Science Research in Early Lesions (TBEL) Centers. TBEL aims to integrate basic and translational cancer research concepts to examine the direct causal relationships and interactions of an early lesion, its microenvironment and host-systemic factors as “co-organizers” of tumor initiation/suppression and malignant progression. The goals of the TBEL program are to further understand the biological and pathophysiological mechanisms driving or restraining precancers and early cancers and facilitate biology-backed precision prevention approaches. FOA 21-061 calls for the TBEL Coordinating and Data Management Center which will coordinate consortium-wide meetings and conferences, and cross-consortium collaborative activities; provide analysis support; and (3) establish program data hub for data capture, curation and management, and protocol development and registration.	<p>Estimated Post Date: 6/1/21</p> <p>Estimated Proposal Due Date: 10/1/21</p>	<p>Up to \$1 million per year, for up to 5 years</p> <p>Dependent upon award mechanism</p>	<p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-060.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-060.html</a></p> <p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-061.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-061.html</a></p>

45.	Pre-Announcement Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed) & Network Coordinating Center (K9CIN; U24 Clinical Trial Not Allowed) (NIH)	NOT-CA-21-068; 069	<p style="text-align: center;"><b>CANCER</b></p> <p>Canine patients with spontaneous tumors closely mimic human conditions and physiology for preclinical immunotherapy research. The network of laboratories and canine clinical trial sites created through this FOA will support canine clinical studies using immunotherapeutic agents and novel drug combinations together with laboratory correlative studies that seek to characterize and understand the cellular and molecular mechanisms that determine anti-tumor responses (or non-responses) in pet dogs with spontaneous tumors. An essential goal of these studies will be to determine whether or not canine cancer is a close model of human malignant disease, and if so, whether immunotherapy alone or in combination with other modalities in canine models will inform the design of therapies in humans. These FOAs are for 1) development of a network to study canine cancer immunotherapy and 2) a coordinating center will work with intramural and extramural NCI staff to develop and manage a steering committee for oversight of network activities.</p>	<p>Estimated Post Date: 7/1/21</p> <p>Estimated Proposal Due Date: 10/5/21</p>	Up to \$2.85 million, for up to 5 years	<p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-068.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-068.html</a></p> <p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-069.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-069.html</a></p>
46.	Pre-Announcement FY21 Rare Cancers Research Program (RCRP) (DoD/CDMRP)	TBA	Three awards are expected to be funded under the FY21 RCRP. They include the Concept Award and Idea Development Awards, which must address the following focus areas: 1) Biology and Etiology, specifically to identify disease-defining molecular pathways, cell context, and microenvironment, 2) Research Model – to develop and validate rare tumor-specific models that can support clinical trial readiness, & 3) Therapy to identify novel therapeutic strategies, including drug repurposing. A third award, the Resource and Community Development Award which must focus on Platform Development –	TBA	<p>Up to \$600,000, for up to 3 years</p> <p>Dependent upon award mechanism</p>	<p><a href="https://cdmrp.army.mil/pubs/press/2021/21rcrppreann">https://cdmrp.army.mil/pubs/press/2021/21rcrppreann</a></p>

47.	FY21Breast Cancer Research Program (BCRP) (DoD/CDMRP)	W81XW H-21-BCRP-BTA12-2; BTA3- 2; BTA4- 2; EOHS- 2; INOV-2; TBCCA-2	<p style="text-align: center;"><b>CANCER</b></p> <p>Applications submitted to the FY21 BCRP must address one or more of the following overarching challenges: Prevent breast cancer, identify determinants of breast cancer initiation, risk, or susceptibility, distinguish deadly from non-deadly breast cancers, conquer the problems of overdiagnosis and overtreatment, identify what drives breast cancer growth; determine how to stop it, identify why some breast cancers become metastatic, determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence, revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival and eliminate the mortality associated with metastatic breast cancer. Four awards are supported. They include: 1) the Breakthrough Award (Four Levels), 2) the Era of Hope Scholar Award, 3) the Innovator Award and 4) the Transformative Breast Cancer Consortium Award.</p>	<p>Pre-Application Due: 8/31/21 6/24/21</p> <p>Proposal Due: 9/17/21 10/5/21</p>	<p>Up to \$25 million, for up to 4 years</p> <p>Dependent upon award mechanism</p>	<p><a href="https://cdmrp.army.mil/funding/pa/FY21-BCRP-BTA12-2.pdf">https://cdmrp.army.mil/funding/pa/FY21-BCRP-BTA12-2.pdf</a></p> <p><a href="https://cdmrp.army.mil/funding/pa/FY21-BCRP-BTA3-2.pdf">https://cdmrp.army.mil/funding/pa/FY21-BCRP-BTA3-2.pdf</a></p> <p><a href="https://cdmrp.army.mil/funding/pa/FY21-BCRP-BTA4-2.pdf">https://cdmrp.army.mil/funding/pa/FY21-BCRP-BTA4-2.pdf</a></p> <p><a href="https://cdmrp.army.mil/funding/pa/FY21-BCRP-EOHS-2.pdf">https://cdmrp.army.mil/funding/pa/FY21-BCRP-EOHS-2.pdf</a></p> <p><a href="https://cdmrp.army.mil/funding/pa/FY21-BCRP-INNOV-2.pdf">https://cdmrp.army.mil/funding/pa/FY21-BCRP-INNOV-2.pdf</a></p> <p><a href="https://cdmrp.army.mil/funding/pa/FY21-BCRP-TBCCA-2.pdf">https://cdmrp.army.mil/funding/pa/FY21-BCRP-TBCCA-2.pdf</a></p>
-----	---	---	--	--	--	---

48.	FY21 Pancreatic Cancer Research Program (PCARP) (DoD/CDMRP)	TBA	<p style="text-align: center;"><b>CANCER</b></p> <p>Applications submitted to the FY21 PCARP must address one or more of the following Focus Areas:</p> <ul style="list-style-type: none"> <li>• Early detection research for pancreatic cancer, including studies of individuals with pre-diabetes and diabetes and/or those in underserved ethnic and minority communities</li> <li>• Supportive care and patient-reported outcomes, quality of life, and perspectives during treatment and survivorship</li> <li>• Understanding the relationship between metabolic disruptions in pancreatic cancer and their systemic effects, including diabetes and cachexia</li> <li>• Understanding precursors, origins, and early progression of pancreatic cancer</li> </ul>	TBA	Up to \$750,000, for up to 2 years	<a href="https://cdmrp.army.mil/pubs/press/2021/21pcarppreann">https://cdmrp.army.mil/pubs/press/2021/21pcarppreann</a>
49.	3D Technologies to Accelerate HTAN Atlas Building Efforts (UH2 Clinical Trial Not Allowed) (NIH)	RFA-CA-21-037	The overarching goal of this FOA is to accelerate research efforts conducted and led by the Human Tumor Atlas Network (HTAN, humantumoratlas.org) via the implementation of three-dimensional (3D) imaging technologies that will allow for a comprehensive view of the dynamic multidimensional ecosystems that define tumors in humans. Each project will lead to the multiplexed 3D characterization of at least one cancer transition investigated by the HTAN (pre-malignant to malignant, primary to metastatic, therapy responsive to resistant). The data and analytical tools generated through this FOA will be made available for use by the research and clinical communities through the activities of the HTAN Data Coordinating Center.	<p>Letter of Intent Due: 5/30/21 10/22/21</p> <p>Proposal Due: 6/30/21 11/22/21</p>	Up to \$250,000 per year, for up to 2 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-037.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-037.html#_Section II. Award 1</a>
50.	Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes (ENICTO) in Cancer Survivors Consortium & ENICTO Coordinating Center (NIH)	RFA-CA-21-031; 32	Through FOA CA-21-031 NCI seeks to support exercise and/or medical nutrition intervention research designed to improve cancer treatment-related outcomes for therapies delivered with curative or life-extending intent to cancer survivors. Projects may include either pediatric or adult cancer patient populations and must identify a treatment-related outcome as a primary endpoint and specify a relevant patient-reported secondary outcome(s). Priority will be given to studies with direct clinical relevance and translational potential. Through FOA CA-21-032 NCI will support a Coordinating Center (CC) to facilitate coordination across the new ENICTO awardee sites. The CC's primary mission will include collaborative scientific contribution and entail administrative and communication responsibilities.	<p>Letter of Intent Due: 6/14/21</p> <p>Proposal Due: 7/14/21</p>	Up to \$875,000 per year, for up to 5 years	<p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-031.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-031.html#_Section II. Award 1</a></p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-032.html#_Section_I_Funding">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-032.html#_Section I. Funding</a></p>

51.	Pre-Announcement Acquired Resistance to Therapy Network (ARTNet) (U54 Clinical Trial Not Allowed) & Coordinating and Data Management Center (U24 Clinical Trial Not Allowed) (NIH)	NOT-CA-21-063; 064	<p style="text-align: center;"><b>CANCER</b></p> <p>NCI intends to issue a FOA that invites applications ARTNet and is reissuance of RFA CA-17-009, which created a Drug Resistance and Sensitivity Network (DRSN) as part of the Cancer Moonshot initiative to accelerate clinical research on drug combinations. While precision oncology approaches are helpful for patient selection based on intrinsic mutations, few strategies exist for acquired resistance including a paucity of research platforms developed from resistant-recurrent tumors. The purpose of the ARTNet is to build upon the DRSN and reprioritize focus on addressing the mechanistic underpinnings of acquired resistance to the full range of treatment modalities. An accompanying FOA announces the NCI's intention to issue a FOA that invites applications for a Coordinating and Data Management Center for ARTNet that will support the overall coordination and research aims of the ARTNet sites.</p>	<p>Estimated Post Date: 7/1/21</p> <p>Estimated Proposal Due Date: 11/1/21</p>	<p>Up to \$1.65 million, per award</p> <p>Dependent upon award mechanism</p>	<p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=333332">https://www.grants.gov/web/grants/view-opportunity.html?opId=333332</a></p> <p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=333329">https://www.grants.gov/web/grants/view-opportunity.html?opId=333329</a></p>
52.	Notice of Special Interest: NCI Administrative Supplement Opportunity for Strategies to Optimize Recruitment and Retention of Cancer Prevention and Symptom Management Clinical Trial Participants (NIH)	NOT-CA-21-070 PA-20-272	<p>This NOSI informs current awardees of NCI cancer prevention and symptom management clinical trial grants of an opportunity for supplemental funding of eligible NCI-supported grant and cooperative agreement awards so that awardees can undertake and evaluate recruitment and retention strategies and thereby facilitate the success of their clinical trial programs. The NCI is providing this opportunity for support of implementation and evaluation of promising clinical trial recruitment and retention strategies for cancer prevention, cancer control, and care delivery clinical trials, as well as quality-of-life studies embedded within treatment and imaging studies. Examples of research strategies that may be supported through supplemental funding requested and obtained through this NOSI and PA-20-272 include but are not limited to the following:</p> <ul style="list-style-type: none"> <li>• Recruitment communication training programs for staff</li> <li>• Database screening tools</li> <li>• Digital approaches to reducing study burden (e.g., telehealth)</li> <li>• Outreach to potential participants' health care providers</li> </ul>	<p>Proposal Due: 6/15/21</p>	<p>Up to \$100,000, for up to 1 years</p>	<p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-070.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-070.html</a></p> <p><a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-272.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-272.html#_Section_II._Award_1</a></p>

53.	Notice of Special Interest: Expanding Cancer Control Research in Persistent Poverty Areas (NIH)	NOT-CA-21-071 PAR-20-077	<b>CANCER</b> The purpose of this Notice is to inform potential applicants about the NCI's special interest in providing resources to support highly collaborative, multi-disciplinary Program Projects (P01s) that focus on the development and conduct of cancer control research in low-income and/or underserved populations living in persistent poverty (PP) areas. NCI is interested in programs that address the challenges and opportunities related to working in partnership with local clinics and other health or public health-related organizations to enhance the prevention of cancer and delivery of cancer care strategies to reduce the burden of cancer in PP areas. Use PAR-20-077 to apply.	Letter of Intent Due: 8/25/21  Proposal Due: 9/25/21	Dependent upon proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-071.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-071.html</a> <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-077.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PAR-20-077.html#_SectionII.Award1</a>
54.	Pre-Announcement Pancreatic Ductal Adenocarcinoma Stromal Reprogramming Consortium (PSRC) & Data Management Center (CDMC) (NIH)	NOT-CA-21-075; 076	NCI intends to issue a FOA that invites applications for PSRC U01 Research Projects. The purpose of the PSRC is to is to develop a comprehensive understanding of PDAC tumor progression, its microenvironment (TME) as a tumor fate determinant and the reciprocal tumor-TME interactions that drive clinical outcomes. The information obtained through these comprehensive studies should expose new biology-backed vulnerabilities that will inform the development and preclinical testing of novel interventions in PDAC. A companion FOA will be issued for a PSRC Coordinating and Data Management Center (CDMC) that will support research projects and activities to enhance and facilitate the mission of PSRC as a whole.	Estimated Post Date: 7/1/21  Estimated Proposal Due Date: 11/1/21	Up to \$990,000, per award	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-075.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-075.html</a> <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-076.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-076.html</a>
55.	Notice of Special Interest: Biology of Lung and Head and Neck Preneoplasia (NIH)	NOT-CA-21-057 PA-20-185; 195	This NOSI seeks applications investigating mechanistic and biological aspects of preneoplasia leading to invasive lung and head and neck (HN) cancers. Despite having better molecular understanding of lung and HN cancers and improved therapies for affected patients, these tumors remain a major health problem globally. While molecular markers of early injury of the aerodigestive epithelial field have been found, relatively little is known about the molecular mechanisms that initiate these preneoplasias and drive their progression to invasive cancer. Additionally, little is known about the immune regulation of premalignancy, including lung and HN preneoplasias. A functional understanding of the key molecular and cellular changes involved in the formation and advancement of lung and HN preneoplasias will enhance our knowledge of oncogenic progression and accelerate development of effective, rationally designed, preventive and therapeutic strategies. PA-20-185 & PA-20-195 can be used to apply to this NOSI.	Proposal Due: 10/5/21 10/16/21	Dependent upon proposal, for up to 5 years  Dependent upon award mechanism	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-057.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-057.html</a> <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html#_SectionII.Award1</a> <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-195.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-20-195.html#_SectionII.Award1</a>

56.	Notice of Special Interest: Early-life Factors and Cancer Development Later in Life (NIH)	NOT-CA-21-074 PA-20-185; 195 PAR-21-190 PAR-19-277 PAR-20-052	<p style="text-align: center;"><b>CANCER</b></p> <p>The NIH Research Project Grant supports a discrete, specified, circumscribed project in scientific areas that represent the investigators' specific interests and competencies and that fall within the mission of the participating NIH Institutes and Centers (ICs). The R01 is the original, and historically the oldest, grant mechanism used by the NIH to support health-related research and development. Research grant applications are assigned to participating ICs based on receipt and referral guidelines and applications may be assigned to multiple participating ICs with related research interests. Applicants are encouraged to identify a participating IC that supports their area of research via the <a href="#">R01 IC-Specific Scientific Interests and Contact</a> website and contact Scientific/Research staff from relevant ICs to inquire about their interest in supporting the proposed research project. This FOA does not accept applications proposing clinical trial(s).</p>	Proposal Due: 6/5/21 6/8/21 6/16/21 6/24/21 11/8/21	Dependent upon proposal, for up to 5 years  Dependent upon award mechanism	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-074.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-074.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html#_Section II. Award 1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-195.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-195.html#_Section II. Award 1</a>
<b>CLINICAL TRIALS (6)</b>						
57.	NICHD Small Research Grant Program (R03 Clinical Trial Required) & (R03 Basic Experimental Studies with Humans Required) (NIH)	PA-21-221; 231	<p>The NICHD Small Research Grant Program supports clinical trials that fall within the NICHD mission. The R03 program may be used for different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. Studies conducted with specific applications toward processes or products in mind should submit to PA-21-221. Types of studies that should submit under FOA 21-231 include studies that prospectively assign human participants to conditions and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.</p>	Proposal Due: 6/16/21 10/16/21	Up to \$50,000 per year, for up to 2 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PA-21-221.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-21-221.html#_Section II. Award 1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-21-231.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-21-231.html#_Section II. Award 1</a>
58.	NINDS Exploratory Clinical Trials (U01 - Clinical Trial Required) (NIH)	PAR-21-236	<p>The purpose of this FOA is to encourage grant applications for investigator-initiated exploratory clinical trials to NINDS. The trials must address questions within the mission and research interests of the NINDS and may include Phase 1 and 2 studies of drugs and biologics, feasibility studies of devices, and early studies of surgical, behavioral or rehabilitation therapies. All exploratory trials must contribute to the justification for, and provide some of the data required to inform a future trial to establish efficacy (such as a Phase 3, Phase 4 or Pivotal trial).</p>	Proposal Due: 6/5/21 10/5/21	Dependent upon proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-236.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-21-236.html#_Section II. Award 1</a>

59.	NeuroNEXT Clinical Trials & Small Business Innovation in Clinical Trials (U01/U44 Clinical Trial Optional) (NIH)	PAR-21-223; 224	<p style="text-align: center;"><b>CLINICAL TRIALS</b></p> <p>This FOA encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies. Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests. Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure.</p>	<p>Proposal Due: 6/5/21 9/5/21 10/5/21</p>	<p>Dependent upon proposal, for up to 5 years</p> <p>Dependent upon award mechanism</p>	<p><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-223.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-21-223.html#_Section_II._Award_1</a></p> <p><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-224.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-21-224.html#_Section_II._Award_1</a></p>
60.	Pragmatic Clinical Studies to Evaluate Patient-Centered Outcomes -- Cycle 2 2021 (PCORI)	N/A	PCORI seeks to fund clinical trials, large simple trials, or large-scale observational studies that compare two or more alternatives for addressing prevention, diagnosis, treatment, or management of a disease or symptom; improving healthcare system-level approaches to managing care; or eliminating health or healthcare disparities. Randomized study designs are strongly encouraged but not required. Proposed studies must address critical clinical choices faced by patients, their caregivers, clinicians, or delivery systems.	<p>Letter of Intent Due: 6/1/21</p> <p>Proposal Due: 8/31/21</p>	Up to \$10 million, for up to 5 years	<a href="https://www.pcori.org/sites/default/files/PCORI-2021-Cycle-2-PCS-PFA.pdf">https://www.pcori.org/sites/default/files/PCORI-2021-Cycle-2-PCS-PFA.pdf</a>
<b>CORONAVIRUS (15)</b>						
61.	Emergency Awards: Community-engaged COVID-19 Testing Interventions & Social, Ethical, and Behavioral Implications Research on Disparities among Underserved and Vulnerable Populations – RADx-UP Phase II (NIH)	RFA-OD-21-008; 009	FOA 21-008 uses an emergency U01 mechanism to support Phase II of the Rapid Acceleration of Diagnostics – Underserved Populations (RADx <sup>SM</sup> -UP) initiative. These two-year Testing Research Projects will (1) expand the scope and reach of RADx <sup>SM</sup> -UP testing interventions to reduce COVID-19 disparities among underserved and vulnerable populations and (2) address scientific questions on interventions to increase access and uptake of COVID-19 testing given the increasing availability of SARS-CoV-2 vaccines. FOA 21-009 is designed to expand research to understand and address the social, ethical, and behavioral implications of COVID-19 testing interventions among underserved and vulnerable populations. Desirable studies for Phase II will move beyond descriptive health disparities research to focus on developing interventions and other actionable solutions in collaboration with community partners and stakeholders. The funding for these initiatives is from the American Rescue Plan Act of 2021.	<p>Proposal Due: 7/7/21</p>	<p>Up to \$750,000 per year, for up to 2 years</p> <p>Dependent upon award mechanism</p>	<p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-21-008.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-21-008.html#_Section_II._Award_1</a></p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-21-009.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-21-009.html#_Section_II._Award_1</a></p>

62.	Pre-Announcement Strengthening environmental health capacity to detect, prevent, and control environmental health hazards through data-driven, evidence-based approaches; pilot EHR/ COVID-19 community mitigation (CDC)	CDC-RFA-EH20-20050101 SUPP21	<p style="text-align: center;"><b>CORONAVIRUS</b></p> <p>The environmental health capacity (EHC) funding opportunity seeks to strengthen the nation's environmental health (EH) capacity to protect public health by strengthening the capacity of public health departments using 3 strategies to address specific EH topics and issues. This will ensure safe and healthy environments and improve community health status. The 3 strategies are (1) using EH data and information, (2) identifying and addressing EH hazards, and (3) assessing the effectiveness and impact of EH interventions. All EHC projects must provided activities, objectives, and performance measures that encompass the three primary EHC strategies. This project will be initiated through the CDC environmental health capacity project Component B and Component C, the purpose of this project is to assess the implementation of COVID-19 community mitigation strategies in communities disproportionately affected by COVID-19. Focus will be on mitigation strategies promoting behaviors that prevent the spread of the virus and maintain healthy environments. Project objectives include identifying any existing challenges and differences in strategy implementation to prevent COVID-19 transmission and reduce impact among racial and ethnic minority groups, people with lower incomes and/or experiencing poverty or homelessness, low-wage essential workers, and rural communities.</p>	<p>Estimated Post Date: 6/16/21</p> <p>Estimated Proposal Due Date: 7/23/21</p>	Up to \$2.3 million, per award	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=333081">https://www.grants.gov/web/grants/view-opportunity.html?opId=333081</a>
63.	Community-Based Workforce for COVID-19 Vaccine Outreach (HHS/HRSA)	HRSA-21-136	The purpose of the program is to establish, expand, and sustain a public health workforce to prevent, prepare for, and respond to COVID-19. This includes mobilizing community outreach workers, which includes community health workers, patient navigators, and social support specialists, to educate and assist individuals in accessing and receiving COVID-19 vaccinations. This includes activities such as conducting face-to-face outreach and reaching out directly to community members to educate them about the vaccine, assisting individuals in making a vaccine appointment, providing resources to find convenient vaccine locations, assisting individuals with transportation or other needs to get to a vaccination site. The program intends to address persistent health disparities by offering support and resources to vulnerable and medically underserved communities, including racial and ethnic minority groups and individuals living in areas of high social vulnerability.	Proposal Due: 5/18/21	Up to \$12.5 million, for up to 6 months	<a href="https://grants.hrsa.gov/2010/Web2External/Interface/FundingCycle/ExternalView.aspx?fCycleID=8be08d26-17be-4e5f-873d-344358f4847a">https://grants.hrsa.gov/2010/Web2External/Interface/FundingCycle/ExternalView.aspx?fCycleID=8be08d26-17be-4e5f-873d-344358f4847a</a>

64.	Pediatric and Perinatal COVID-19 Registry (U18) Clinical Trials Optional (FDA)	RFA-FD-21-035	<p style="text-align: center;"><b>CORONAVIRUS</b></p> <p>This program supports development of a compendium-type resource incorporating pediatric and perinatal COVID-19 registries, natural history, and other data. A compendium would (i) provide a resource for clinical &amp; health services researchers, and drug developers to analyze data to broadly understand the natural history of disease and clinical outcomes in these specific populations; (ii) allow for linking of mother-infant pair data in order to evaluate the risk of newborns contracting COVID-19 from mothers who test positive for the virus; and (iii) assess the short and longer-term outcomes in neonates and infants who are perinatally exposed to and/or test positive for SARS CoV-2.</p>	Letter of Intent Due: 5/21/21  Proposal Due: 7/6/21	Up to \$1 million per year, for up to 2 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-21-035.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-21-035.html#_Section_II_Award_1</a>
65.	Notice of Special Interest to add COVID-19 Capacity Building Grants to PAR-18-604 Vet-LIRN Network Capacity-Building Projects (Vet-LIRN) (FDA)	NOT-FD-21-014  PAR-18-604	<p>The purpose of this notice is to inform potential applicants to the Vet-LIRN, about a special interest in applications focusing on COVID-19 animal diagnostics. This notice invites Vet-LIRN Network Laboratories to submit grant applications for Projects or Equipment, specifically related to work focusing on COVID-19 diagnostics in animals. Examples of approaches that are encouraged include, but are not limited to those listed below:</p> <ul style="list-style-type: none"> <li>• Building testing and sequencing capacity</li> <li>• Serological testing to detect past infections in animals</li> <li>• Investigating performance of various diagnostic kits</li> <li>• New detection methods, such as to detect multiple respiratory viruses in a single test</li> </ul>	Proposal Due: 7/12/21	Up to \$225,000 per year, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-FD-21-014.html">https://grants.nih.gov/grants/guide/notice-files/NOT-FD-21-014.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/par-18-604.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/par-18-604.html#_Section_II_Award_1</a>
66.	Notice of Special Interest: Research on the Impact of the Covid 19 Pandemic and Risks for Abuse and Injury Among Vulnerable Children and Youth (NIH)	NOT-HD-21-026  PA-20-183; 185; 194; 195; 196; 200;  PA-21-221; 231	<p>Treating injured and traumatized children and efforts to implement preventive interventions have become increasingly challenging in the context of the current pandemic. Children are notably at greater risk of injury, morbidity and mortality due to the social isolation, economic stressors, and other challenges related to policies and practices designed to mitigate the spread of the coronavirus. Given the limitations of traditional contexts for identifying and reporting abuse due to these mitigation strategies, research on treatment and care in diverse settings is essential to identify effective ways of screening, diagnosing and assessing trends in abuse and abuse related injuries in this current context. It is anticipated that research stemming from this NOSI will help to provide greater recognition of the need for better resources and support for vulnerable children. Multiple FOAs can be used to apply to this NOSI.</p>	Proposal Due: 6/5/21 6/16/21 10/5/21 10/16/21	<p>Dependent upon proposal, for up to 5 years</p> <p>Dependent upon award mechanism</p>	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-HD-21-026.html">https://grants.nih.gov/grants/guide/notice-files/NOT-HD-21-026.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-20-183.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/pa-20-183.html#_Section_II_Award_1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html#_Section_II_Award_1</a>

<b>DIABETES (2)</b>						
67.	Support for SBIR to Develop Technologies for Development and Integration of Novel Components for Open and Closed Loop Hormone Replacement Platforms for T1D Therapy (NIH)	RFA-DK-21-011	This FOA is intended to support cutting edge research conducted by small business leading to the development of innovative technologies that may advance progress toward integrated, long term, wearable/implantable, glucose regulated open and closed loop insulin/pancreatic hormone delivery systems. This announcement has two main purposes: a) to promote technical innovation and b) to conduct pre-clinical testing of single or combined components of open and closed loop systems. Research topics that this announcement intends to attract include but are not limited to: 1) Glucose sensors and pancreatic hormones delivery systems, 2) Algorithms and Integrated Systems & Pre-Clinical Testing.	Letter of Intent Due: 1/9/22  Proposal Due: 2/9/22	Up to \$4.3 million, for up to 3 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-011.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-011.html#_Section_II_Award_1</a>
68.	Standardization of C-Peptide and HbA1C Measurements Program (U01 Clinical Trial Not Allowed) (NIH)	RFA-DK-21-007	In the research sphere, the measurement of C-peptide used to monitor endogenous insulin production is the basis for identifying successful therapeutics to delay the progression of type 1 diabetes. There is increasing evidence, including data from the DCCT study, that preservation of even a low level of endogenous insulin production in people with type 1 diabetes is associated with significantly fewer diabetes complications over the longer term. Therefore, efficient, accurate, and precise measurement of C-peptide is important for current and future research with the goal to prevent type 1 diabetes in those at risk. This Funding Opportunity Announcement will provide support for a Central Primary Reference Laboratory (CPRL) to standardize and improve the measurement of HbA1c and C-peptide.	Letter of Intent Due: 9/20/21  Proposal Due: 10/20/21	Up to \$550,000, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-007.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-007.html#_Section_II_Award_1</a>
<b>DRUG DEVELOPMENT &amp; PHARMACOLOGY (1)</b>						
69.	Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (NIH)	PAR-21-233	This FOA supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, gene-based therapies, cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors for biotherapeutic candidates developed in this program.	Letter of Intent Due: 7/10/21  Proposal Due: 8/10/21	Up to \$500,000 per year, for up to 2 years (Phase I) & Up to \$1.5 million per year, for up to 3 years (Phase II)	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-233.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-21-233.html#_Section_II_Award_1</a>

			<b>DUCHENNE MUSCULAR DYSTROPHY (1)</b>			
70.	Pre-Announcement FY21Duchenne Muscular Dystrophy Research Program (DMDRP) (DoD/CDMRP)	TBA	Two awards are expected to be funded under the FY21 DMDRP. They include 1) Idea Development Award: supports development of innovative, high-impact ideas that advance the understanding of Duchenne muscular dystrophy (DMD) and ultimately lead to improved outcomes & 2) Translational Research Award: Supports translational studies that have moved beyond the realm of basic research and have the potential to result in a near-term impact in clinical research or the clinic.	TBA	Up to \$1.3 million, for up to 3 years  Dependent upon award mechanism	<a href="https://cdmrp.army.mil/pubs/press/2021/21dmdrppreann">https://cdmrp.army.mil/pubs/press/2021/21dmdrppreann</a>
			<b>FORENSIC SCIENCE (1)</b>			
71.	Research and Evaluation for the Testing and Interpretation of Physical Evidence in Publicly Funded Forensic Laboratories (DOJ)	O-NIJ-2021-95002	With this solicitation, NIJ seeks proposals for rigorous research and evaluation projects that will: 1) Identify and inform the forensic community of best practices through the evaluation of existing laboratory protocols, & 2) Have a direct and immediate impact on laboratory efficiency and assist in making laboratory policy decisions. The intent of this program is to direct the findings of the research and evaluation toward the identification of the most efficient, accurate, reliable, and cost-effective methods for the identification, analysis, and interpretation of physical evidence for criminal justice purposes.	Proposal Due: 6/3/21	Up to \$500,000 per year, for up to 5 years	<a href="https://nij.ojp.gov/sites/g/files/xyckuh171/files/media/document/O-NIJ-2021-95002.pdf">https://nij.ojp.gov/sites/g/files/xyckuh171/files/media/document/O-NIJ-2021-95002.pdf</a>
			<b>GENOMICS (3)</b>			
72.	Evaluating Genetic and Genomic Medicine Implementation and Outcomes in the Regional Genetics Networks (HHS/HRSA)	HRSA-21-110	This notice announces the opportunity to apply for supplemental funding under the Regional Genetics Networks (RGN) program. The purpose of this Evaluating Genetic and Genomic Medicine Implementation and Outcomes in the Regional Genetics Network (EGMIO-RGN) project is to evaluate the implementation and outcomes of selected RGN program activities aimed to improve access to services for individuals with, or at risk for, genetic or genomic conditions and their families, especially those among underserved populations. This evaluation will be used to inform the RGN recipients and the field of genetic and genomic medicine with best practices and strategies to implement genetic and genomic advances into clinical and public health.	Proposal Due: 6/7/21	Up to \$165,000 per year, for up to 3 years	<a href="https://grants.hrsa.gov/2010/Web2External/Interface/FundingCycle/ExternalView.aspx?fCycleID=7d831f34-ff58-41d1-9ec1-37b9481c2a62">https://grants.hrsa.gov/2010/Web2External/Interface/FundingCycle/ExternalView.aspx?fCycleID=7d831f34-ff58-41d1-9ec1-37b9481c2a62</a>

73.	Pre-Announcement Non-Human Primate Developmental Genotype-Tissue Expression (NHP dGTEx) Project (U24 Clinical Trials Not Allowed) (NIH)	NOT-HG-21-027	<p style="text-align: center;"><b>GENOMICS</b></p> <p>The purpose of this Notice is to alert the community that NHGRI plans to publish a FOA for a new Non-Human Primate Developmental Genotype-Tissue Expression (NHP dGTEx) project. This project is intended to provide funds for non-human primate (NHP) tissue collections and genomic assays for comparative genomic assessment to address gaps in our understanding of tissue-specific gene expression at distinct developmental stages. The FOA is expected to be published in Spring of 2021 with an expected application due date in the Summer of 2021. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This FOA will utilize the U24 funding mechanism.</p>	Estimated Proposal Due Date: 8/2/21	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=333330">https://www.grants.gov/web/grants/view-opportunity.html?opId=333330</a>
74.	Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed) (NIH)	PAR-21-229	<p>Large quantities of genomic data collected from pediatric birth defects cohorts are available to the research community through several databases such as the Database of Genotypes and Phenotypes (dbGaP), the Gabriella Miller Kids First Data Resource Portal, the European Genome-Phenome Archive and Clinical Genome Resource (ClinGen). The purpose of this initiative is to promote the screening, functional validation and characterization of birth defects-associated genetic variants identified through public facing databases and individual efforts using in-silico tools, appropriate animal models, <i>in vitro</i> systems or multi-pronged approaches.</p>	Letter of Intent: 1/5/22  Proposal Due: 2/5/22	Up to \$499,999 per year, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-229.html#SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PAR-21-229.html# Section II. Award 1</a>
			<b>HEARING (2)</b>			
75.	Pre-Announcement Hearing Restoration Research Program (HRRP) (DoD/CDMRP)	TBA	<p>HRRP applications must address one or more of the following areas:</p> <ul style="list-style-type: none"> <li>• Accelerate translation of biological regeneration/repair mechanisms into therapies that treat auditory system injury</li> <li>• Diagnostic tests that help differentiate sensory, neural, synaptic, and central processing disorders, that may inform applicability and outcomes for current or future hearing restoration therapeutics.</li> <li>• Develop reliable in-vitro human models to facilitate the understanding, derivation and characterization of human auditory cells, and/or to facilitate the evaluation of hearing restoration therapies.</li> <li>• Develop and/or validate techniques/methods beyond the audiogram to diagnose acute auditory system injury in austere or remote environments.</li> </ul> <p>All applications are to be submitted under the Focused Research Award</p>	TBA	Up to \$1.25 million, for up to 3 years	<a href="https://cdmrp.army.mil/pubs/press/2021/21hrrppreann">https://cdmrp.army.mil/pubs/press/2021/21hrrppreann</a>

76.	Pediatric Audiology Competitive Supplement to Leadership Education in Neurodevelopmental and Related Disabilities (LEND) (HHS/HRSA)	HRSA-21-042	<p style="text-align: center;"><b>HEARING</b></p> <p>This notice announces the opportunity for LEND program recipients to apply for funding under the Pediatric Audiology Competitive Supplement to the LEND program. This supports the clinical and leadership training of pediatric audiology trainees within LEND programs as well as continuing education for practicing professionals. The program aims to achieve the following goals: to strengthen the focus on screening, treatment, and follow-up in infants and young children who are deaf or hard-of-hearing (DHH) and who have or are at risk for autism spectrum disorder (ASD) and/or other developmental disabilities (DD); to increase the number of pediatric audiologists with clinical and leadership skills and expertise in delivering care to infants and young children with ASD/DD, utilizing these unique skills to work across disciplines to better serve children with hearing loss</p>	Proposal Due: 7/1/21	Up to \$75,000 per year, for up to 5 years	<a href="https://grants.hrsa.gov/2010/Web2External/Interface/FundingCycle/ExternalView.aspx?fCycleID=9d80a1db-ea1e-4ff6-bef9-64651ad53e95">https://grants.hrsa.gov/2010/Web2External/Interface/FundingCycle/ExternalView.aspx?fCycleID=9d80a1db-ea1e-4ff6-bef9-64651ad53e95</a>
			<b>INFECTIOUS &amp; IMMUNE-MEDIATED DISEASES (2)</b>			
77.	Systems Approach to Understand Mechanisms of Heterogeneous Response to Influenza (R01 Clinical Trial Not Allowed) (NIH)	RFA-AI-21-017	The purpose of this FOA is to support the identification of mechanisms behind heterogeneous responses in the population to influenza infection and/or vaccination through development and application of computational tools. This initiative will recruit computational expertise to develop tools and perform analyses that enable the discovery of mechanisms driving heterogeneous response to influenza vaccine or infection. Pursuing the development of these tools could reveal correlates of protection in distinct populations such as children, elderly and immuno-compromised individuals, , as well as reveal novel pathways to target for improved breadth or durability of vaccines. If successful, this research could reveal new vaccine strategies, thus improving and de-risking influenza vaccine design.	Letter of Intent Due: 8/8/21  Proposal Due: 9/8/21	Dependent upon proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-017.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-017.html#_Section_II._Award_1</a>
78.	Integrated Pathogen Reduction Technologies for whole blood and blood components for transfusion (R01) Clinical Trials Not Allowed (FDA)	RFA-FD-21-032	This RFA supports the Center of Biologics Evaluation and Research in identifying pathogen inactivation technology that could be applied to whole blood at the point of collection or just after, followed by separation of that blood into components, potentially reducing or eliminating donor deferral and/or testing requirements. This project involving a moderately-sized pilot program would assess the feasibility of the widespread introduction of pathogen inactivation of whole blood that is collected. The request would cover completion of necessary preparatory basic laboratory-based research work, purchase of the necessary equipment, and contracting for the blood banking services required for the demonstration of the feasibility of this approach.	Letter of Intent Due: 5/19/21  Proposal Due: 7/6/21	Up to \$4 million per year, for up to 2 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-21-032.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-21-032.html#_Section_II._Award_1</a>

<b>MANUFACTURING (1)</b>						
79.	Defense Manufacturing Communities Support Program (DoD)	OLDCC-21-F-0001	The Defense Manufacturing Community Support Program is designed to undertake long-term investments in critical skills, facilities, research and development, and small business support in order to strengthen the national security innovation and manufacturing base. The program also seeks to ensure complementarity of those communities so designated with existing Defense Manufacturing Institutes. Defense Manufacturing Institutes are manufacturing ecosystems established since 2014, with common manufacturing and design challenges revolving around specific technologies. This notice announces an opportunity to obtain Defense Manufacturing Community designation and funding under the Defense Manufacturing Community Support Program for Fiscal Year 2021.	Proposal Due: 6/15/21	Up to \$5 million, for up to 5 years	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=332164">https://www.grants.gov/web/grants/view-opportunity.html?opId=332164</a>  (Full Announcement in Related Documents Tab)
<b>MENTAL &amp; BEHAVIORAL HEALTH (8)</b>						
80.	Identification of Positive Valence System Related Targets for Novel Suicide Prevention Approaches (R01/R21 Clinical Trial Optional) (NIH)	PAS-21-215; 216	These FOAs solicit applications for research projects that will advance translational research to better understand risk and resilience for suicide in the context of the NIMH Research Domain Criteria (RDoC) framework, specifically the Positive Valence Systems (PVS) domain, and lead to novel interventions. The projects should focus on the identification of novel behavioral or neurobiological intervention targets for the treatment of suicidality. NIMH is particularly interested in the role of PVS deficits in suicidal thoughts and behaviors, identification of unique subtypes by behavior and neural circuitry, and associations between PVS-related subtypes and other RDoC domains in relation to suicidality.	Letter of Intent Due: 9/5/21 5/16/21  Proposal Due: 10/5/21 10/16/21	Dependent upon proposal, for up to 5 years  Dependent upon award mechanism	<a href="https://grants.nih.gov/grants/guide/pa-files/PAS-21-215.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PAS-21-215.html#_Section_II._Award_1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PAS-21-216.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PAS-21-216.html#_Section_II._Award_1</a>
81.	Systems-Level Risk Detection and Interventions to Reduce Suicide, Ideation, and Behaviors in Black Children and Adolescents (R01/R34 Clinical Trial Optional) (NIH)	RFA-MH-21-185; 186	FOA 21-185 invites testing of interventions and strategies that are designed to be delivered in typical service settings using commonly available personnel and resources, to enhance the implementation of interventions that prove effective, enhance their future uptake in diverse settings, and thereby reduce risk of suicide and self-harm. This FOA encourages research focused on systems-level interventions and is not intended to support the development or testing of new screening tools, assessment instruments, or individual-level preventive or therapeutic interventions. The companion FOA, 21-186 supports pilot work for subsequent research to test the effectiveness of combined interventions to both detect and intervene to reduce risk of suicide and suicide ideation and behavior, and non-suicidal self-injury specifically among Black children and adolescents.	Letter of Intent Due: 5/29/21  Proposal Due: 6/29/21	Dependent upon proposal, for up to 5 years  Dependent upon award mechanism	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-185.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-185.html#_Section_II._Award_1</a>  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-186.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-186.html#_Section_II._Award_1</a>

82.	Systems-Level Risk Detection and Interventions to Reduce Suicide, Ideation, and Behaviors in Youth from Underserved Populations (R01/R34 Clinical Trial Optional) (NIH)	RFA-MH-21-187; 188	<p style="text-align: center;"><b>MENTAL &amp; BEHAVIORAL HEALTH</b></p> <p>These initiatives support research to test the effectiveness of combined strategies to both detect and intervene to reduce the risk of suicide and suicide ideation and behavior (SIB) and/or non-suicidal self-harm (NSSI) by youth from populations that are often underserved by the mental health system. FOA 21-187 encourages services research aimed at testing easily implemented systems-level interventions and strategies that improve systematic risk identification, coordinated referral to, or engagement and retention in quality care for prevention of SIB and/or NSSI among adolescents and children from the targeted populations. Opportunities for detection and prevention in youth may occur at various points of contact across an array of mental health specialty and non-specialty settings. FOA 21-188 supports pilot studies in these same areas.</p>	<p>Letter of Intent Due: 5/29/21</p> <p>Proposal Due: 6/29/21</p>	<p>Dependent upon proposal, for up to 5 years</p> <p>Dependent upon award mechanism</p>	<p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-187.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-187.html#_SectionII.Award1</a></p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-188.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-188.html#_SectionII.Award1</a></p>
83.	PCORI Funding Announcement: Comparative Effectiveness of Interventions Targeting Mental Health Conditions in Individuals with Intellectual and Developmental Disabilities (PCORI)	N/A	<p>PCORI seeks to fund randomized controlled trials (RCTs) and/or observational studies that focus on comparative effectiveness of interventions targeting mental health conditions in individuals with intellectual and developmental disabilities (IDD). PCORI's tPFA will solicit applications that respond to the following question: What is the comparative effectiveness of evidence-based approaches (e.g., specific pharmacologic and behavioral interventions) that address mental health conditions in individuals with IDD? Proposed studies should compare the effectiveness of pharmacological, behavioral, other nonpharmacological or combination interventions administered via appropriate delivery modalities (e.g., telehealth, family-based, collaborative care, group or individual).</p>	<p>Letter of Intent Due: 6/1/21</p> <p>Proposal Due: 8/31/21</p>	<p>Up to \$3 million, for up to 3 years</p>	<p><a href="https://www.pcori.org/sites/default/files/PCORI-2021-Cycle-2-IDD-PFA.pdf">https://www.pcori.org/sites/default/files/PCORI-2021-Cycle-2-IDD-PFA.pdf</a></p>
84.	NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed) (NIH)	PA-21-235	<p>The NIMH Exploratory/Developmental Grant program supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data. The preliminary work from these studies could lead to a major impact on biomedical, behavioral, or clinical mental health research, or on the delivery of mental health care.</p>	<p>Proposal Due: 6/16/21 10/16/21</p>	<p>Dependent upon proposal, for up to 3 years</p>	<p><a href="https://grants.nih.gov/grants/guide/pa-files/PA-21-235.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-21-235.html#_SectionII.Award1</a></p>

NEUROFIBROMATOSIS (6)						
85.	FY21 Neurofibromatosis Research Program (NFRP) (DoD/CDMRP)	W81XW H-21-NFRP-CTA; EHDA; IIRA; NIA; EIRA; SIA	Applications to NFRP must address one or more of the following areas of interest in neurofibromatosis: (1) Biomarker discovery, utility, development, and validation, (2) Non-tumor manifestations, (3) Heterogeneity of NF tumors, (4) Novel disease and treatment response markers, (5) preclinical efficacy studies, (5) target identification, (6) modifiers of NF and (7) Health services research. Six awards have been released. They include, (1) Clinical Trial Award: funds Phase 0, I, or II clinical trials relevant to NF and/or schwannomatosis, (2) Exploration - Hypothesis Development Award: funds high-risk, high gain concepts in NF research, (3) Investigator-Initiated Research Award: Funds highly rigorous, high-impact research projects, (4) New Investigator Award: Supports the continued development of promising independent investigators, (5) Early Investigator Research Award: Supports research opportunities focused on NF for individuals in the early stages of their careers and (6) Synergistic Idea Award: supports partnerships between two or three investigators to address an innovative question or problem in NF. Release seventh award in this program, Clinical Trials Consortium, is pending.	Pre-Application Due: 7/8/21  Proposal Due: 7/22/21  Letters of Reference Due: 7/27/21	Up to \$2 million, for up to 3 years  Dependent upon award mechanism	<a href="https://cdmrp.army.mil/funding/pa/FY21-NFRP-CTA.pdf">https://cdmrp.army.mil/funding/pa/FY21-NFRP-CTA.pdf</a>  <a href="https://cdmrp.army.mil/funding/pa/FY21-NFRP-EHDA.pdf">https://cdmrp.army.mil/funding/pa/FY21-NFRP-EHDA.pdf</a>  <a href="https://cdmrp.army.mil/funding/pa/FY21-NFRP-IIRA.pdf">https://cdmrp.army.mil/funding/pa/FY21-NFRP-IIRA.pdf</a>  <a href="https://cdmrp.army.mil/funding/pa/FY21-NFRP-NIA.pdf">https://cdmrp.army.mil/funding/pa/FY21-NFRP-NIA.pdf</a>  <a href="https://cdmrp.army.mil/funding/pa/FY21-NFRP-EIRA.pdf">https://cdmrp.army.mil/funding/pa/FY21-NFRP-EIRA.pdf</a>  <a href="https://cdmrp.army.mil/funding/pa/FY21-NFRP-SIA.pdf">https://cdmrp.army.mil/funding/pa/FY21-NFRP-SIA.pdf</a>
NEUROSCIENCE & NEUROLOGY (14)						
86.	CENTER OF EXCELLENCE (COE): Brain-Derived Neuromorphic Computing with Intelligent Materials (DoD/AFRL)	FOA-AFRL-AFOSR-2021-0005	This Center of Excellence is anticipated to extend the research interests of AFRL in the topical area of neuromorphic computing and provide opportunities for a new generation of US scientists and engineers to address United States Space Force and United States Air Force research needs. This is a special FOA because it explicitly calls for (a) research in the high-priority Air Force interest areas of neuroscience, neuromorphic computing, and nanomaterials; and (b) education of students within the US in vital technology areas with opportunities for potential recruitment of US nationals for employment at AFRL.	White Paper Due: 6/1/21  Proposals Due: 8/16/21	Up to \$1 million per year, for up to 5 years	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=332883">https://www.grants.gov/web/grants/view-opportunity.html?opId=332883</a>  (Full Announcement in Related Documents Tab)

87.	Translational Neural Devices (UG3/UH3/U44 Clinical Trial Optional) (NIH)	RFA-NS-21-021; 022	<p style="text-align: center;"><b>NEUROSCIENCE &amp; NEUROLOGY</b></p> <p>The purpose of these FOAs is to encourage investigators to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent small clinical study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments due to the novelty of the device or its intended use.</p>	<p>Letter of Intent Due: 6/1/21 9/20/21</p> <p>Proposal Due: 7/1/21 10/20/21</p>	<p>Up to \$1 million, per year, for up to 4 years (Phase I) &amp; Up to \$1.5 million for up to 4 years (Phase II)</p>	<p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-021.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-021.html#_SectionII.Award1</a></p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-022.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-022.html#_SectionII.Award1</a></p>
88.	BRAIN Initiative Cell Atlas Network (BICAN): Comprehensive Center on Human and Non-human Primate Brain Cell Atlases, Specialized Collaboratory on Human, Non-human Primate, and Mouse Brain Cell Atlases & Coordinating Unit for Biostatistics, Informatics, and Engagement (CUBIE) (NIH)	NOT-MH-21-260; 261; 262	<p>The overarching goal of the BICAN is to build reference brain cell atlases that will be widely used throughout the research community, providing a molecular and anatomical foundational framework for the study of brain function and disorders. Three FOAs are expected to be issued under BICAN. NOT MH 21-260 will support a group of large-scale Comprehensive Centers that will adopt scalable technology platforms and streamlined sampling strategies and assay cascade to create comprehensive and highly granular brain cell atlases of human and non-human primates with an emphasis on human. The Centers are expected to characterize all brain cell types at high-resolution. NOT MH 21-261 will support a group of Specialized Collaboratories that will adopt scalable technology platforms and streamlined sampling strategies and assay cascade to complement the Comprehensive Centers with distinct capabilities, competencies, and research aims in creating brain cell atlases. The Collaboratories are expected to have specialized research focus on select brain regions and/or cell types in human and non-human primates, or to extend mouse brain cell atlases across lifespan with a new emphasis on linking molecular cell types to circuits and function. NOT MH 21-262 will support an integrated Coordinating Unit of Biostatistics, Informatics, and Engagement (CUBIE) that will be composed of four subunits to establish respectively (1) a common sequencing data processing pipeline, (2) a common imaging data processing pipeline, (3) a comprehensive brain cell knowledge base, and (4) an engagement and outreach element to coordinate the research activities within and beyond the BICAN.</p>	<p>Estimated Post Date: 7/1/21</p> <p>Estimated Proposal Due Date: 11/9/21</p>	<p>Dependent upon proposal</p>	<p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=333333">https://www.grants.gov/web/grants/view-opportunity.html?opId=333333</a></p> <p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=333334">https://www.grants.gov/web/grants/view-opportunity.html?opId=333334</a></p> <p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=333335">https://www.grants.gov/web/grants/view-opportunity.html?opId=333335</a></p>

89.	BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional) (NIH)	RFA-NS-21-023; 024	<p style="text-align: center;"><b>NEUROSCIENCE &amp; NEUROLOGY</b></p> <p>These FOAs encourage investigators to pursue translational activities and small clinical studies for recording and/or stimulating devices to treat central nervous system disorders and better understand the human brain. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study, as well as a subsequent small clinical study. Only Significant Risk (SR) clinical studies that will require an Investigational Device Exemption (IDE) from the FDA, such as chronic implants, will be supported by this FOA.</p>	<p>Letter of Intent Due: 8/20/21 9/20/21</p> <p>Proposal Due: 10/20/21</p>	<p>Up to \$7.5 million, for up to 5 years</p> <p>Dependent upon award mechanism</p>	<p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-023.html#_Section_II.Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-023.html#_Section_II.Award_1</a></p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-024.html#_Section_II.Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-024.html#_Section_II.Award_1</a></p>
90.	BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed) (NIH)	RFA-MH-21-175	<p>This FOA solicits applications to develop next-generation, innovative technologies to define and target specific cell types in the brain. Of particular interest are first-in-class and/or cross-cutting non-invasive or minimally invasive techniques that permit repeated measurements from cells over time in a non-destructive manner. Tools/technologies relevant for this initiative are expected to be transformative, either through the development of novel tools that may be high-risk or through major advances in current approaches that break through technical barriers and will significantly improve current capabilities. An emphasis of the BRAIN initiative is the development of novel tools to study the brain, and here we highlight the need for innovative approaches to bridge experimental scales. Studies that are able to explore molecular and cellular mechanisms of neural activity permitting improved precision and sensitivity in the analysis of micro- and macro-circuits are strongly encouraged.</p>	<p>Letter of Intent Due: 9/8/21</p> <p>Proposal Due: 10/8/21</p>	<p>Dependent upon proposal, for up to 3 years</p>	<p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-175.html#_Section_II.Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-175.html#_Section_II.Award_1</a></p>
91.	Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional) (NIH)	PA-21-219	<p>The Joint NINDS/NIMH Exploratory Neuroscience Research Grant program supports exploratory and innovative research projects, which fall within the missions of the NINDS and NIMH. Awards will provide support for the early and conceptual stages of projects. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs in the understanding of important areas of neuroscience, or to the development of novel techniques, agents, methodologies, or models, of high value to the neuroscience community. While this funding opportunity also accepts clinical trials, only applications proposing “mechanistic clinical trials or studies” or basic experimental studies with humans (BESH) will be supported.</p>	<p>Proposal Due: 6/16/21 10/16/21</p>	<p>Up to \$275,000, for up to 2 years</p>	<p><a href="https://grants.nih.gov/grants/guide/pa-files/PA-21-219.html#_Section_II.Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-21-219.html#_Section_II.Award_1</a></p>

92.	FY21 Multiple Sclerosis Research Program (MSRP) (DoD/CDMRP)	W81XW H-21-MSRP-CTA; EIRA; EHDA; IIRA	<p style="text-align: center;"><b>NEUROSCIENCE &amp; NEUROLOGY</b></p> <p>Four awards are funded under the FY21 MSRP. They include: 1) Clinical Trial Award: Supports early-phase, proof-of-principle MS clinical trials to demonstrate feasibility or inform the design of more advanced trials or supports larger scale clinical trials at phase 1 or 2 to determine efficacy (benefit on clinical or preclinical outcomes) in relevant patient populations, 2) Early Investigator Research Award: supports MS-focused research opportunities for individuals in the early stages of their careers, 3) Exploration - Hypothesis Development Award: Supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the MS research field, and 4) Investigator-Initiated Research Award: Supports highly rigorous, high-impact research with the potential to make an important contribution to MS research.</p>	<p>Pre-Application Due: 6/30/21 9/7/21</p> <p>Proposal Due: 10/6/21</p>	<p>Up to \$3 million, for up to 4 years</p> <p>Dependent upon award mechanism</p>	<p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=333436">https://www.grants.gov/web/grants/view-opportunity.html?opId=333436</a></p> <p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=333444">https://www.grants.gov/web/grants/view-opportunity.html?opId=333444</a></p> <p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=333423">https://www.grants.gov/web/grants/view-opportunity.html?opId=333423</a></p> <p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=333437">https://www.grants.gov/web/grants/view-opportunity.html?opId=333437</a></p> <p>(Full Announcement in Related Documents Tab)</p>
			<b>ORAL HEALTH (1)</b>			
93.	Addressing Social Determinants of Health to Eliminate Oral Health Disparities (UG3/UH3 Clinical Trials Optional) (NIH)	RFA-DE-22-002	This FOA supports research on how to effectively identify and optimally address upstream social determinants of health that can often present as a barrier to optimal oral health, impede the effectiveness of interventions, and contribute to oral health disparities in vulnerable and underserved groups. This FOA will encourage multi-disciplinary collaborations, mechanistic research, multi-level research, and/or the use of systems science research approaches. Applications in response to this FOA must propose research that involves improving oral health outcomes through addressing or better understanding one or more upstream social determinants of health.	<p>Letter of Intent Due: 6/8/21</p> <p>Proposal Due: 7/8/21</p>	<p>Dependent upon proposal, for up to 6 years</p>	<p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DE-22-002.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-DE-22-002.html#_Section_II_Award_1</a></p>

<b>ORTHOPAEDIC RESEARCH (3)</b>						
94.	FY21 Peer Reviewed Orthopaedic Research Program (PRORP) (DoD/CDMRP)	W81XW H-21-PRORP-ARA; CTA; CTRA	Three award mechanisms are expected to be funded: They include: 1) Applied Research Award: Focused on advancing optimal treatment and restoration of function for individuals with musculoskeletal injuries sustained during combat, combat-related activities, and non- battle injuries that impact unit readiness and the ability to return to duty/work, 2) Clinical Trial Award: Supporting rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of military combat-related orthopaedic injuries, and 3) Clinical Translational Research Award: Supporting high-impact and/or new/emerging clinical research that may or may not be ready for a full-scale randomized controlled clinical trial.	Pre-Application Due: 5/27/21  Proposal Due: 9/10/21	Up to \$2.75 million, for up to 4 years  Dependent upon award mechanism	<a href="https://cdmrp.army.mil/funding/pa/FY21-PRORP-ARA.pdf">https://cdmrp.army.mil/funding/pa/FY21-PRORP-ARA.pdf</a>  <a href="https://cdmrp.army.mil/funding/pa/FY21-PRORP-CTA.pdf">https://cdmrp.army.mil/funding/pa/FY21-PRORP-CTA.pdf</a>  <a href="https://cdmrp.army.mil/funding/pa/FY21-PRORP-CTRA.pdf">https://cdmrp.army.mil/funding/pa/FY21-PRORP-CTRA.pdf</a>
<b>PEDIATRICS (1)</b>						
95.	Pilot Effectiveness Trials of Interventions for Preschoolers with ADHD (R34 Clinical Trial Required) (NIH)	RFA-MH-21-230	NIMH seeks applications for pilot projects to evaluate the preliminary effectiveness of interventions targeting preschool ADHD symptoms and impairments. An emphasis is placed on studies that take a theory-driven, empirical approach to developing and testing interventions intended to impact current ADHD symptoms and impairments and/or prevent or forestall the emergence of co-occurring disorders or additional ADHD-related impairments. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach, to address whether the intervention engages the target mechanisms presumed to underlie the intervention effects, and to obtain preliminary data needed to inform a larger, more definitive test of the intervention.	Letter of Intent Due: 6/1/21  Proposal Due: 7/1/21	Up to \$450,000, for up to 3 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-230.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-230.html#_Section II. Award 1</a>

POPULATION HEALTH (1)						
96.	Population Dynamics Centers Research Infrastructure Program (P2C Clinical Trial Not Allowed) & Coordinating Center for the NICHD Population Dynamics Centers Research Infrastructure Program (R24 Clinical Trial Not Allowed) (NIH)	RFA-HD-22-013; 014	The goal of FOA 22-013 is to advance the field of population dynamics research by increasing research impact, innovation, and productivity; developing junior scientists; and maximizing the efficiency of research support. This will provide funding for population dynamics infrastructure cores at already productive population research centers. Applicant centers must have a record of high impact, innovative publications and competitiveness for peer-reviewed external funding for research within the scientific mission of the NICHD Population Dynamics Branch (PDB). The goal of FOA 22-014 is to support a coordinating center for the NICHD Population Dynamics Centers Research Infrastructure Programs, with two primary objectives: 1) To improve the translation and dissemination of major peer-reviewed findings, methods, and perspectives from population dynamics research to multiple audiences & 2) to improve coordination and cooperation across the NICHD Population Dynamics Centers Research Infrastructure Programs in order to enhance the productivity and scientific impact of the NICHD Population Dynamics Centers Research Infrastructure Programs and of population dynamics research overall.	Letter of Intent Due: 6/29/21  Proposal Due: 7/29/21	Up to \$500,000, for up to 5 years  Dependent upon award mechanism	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-22-013.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-22-013.html#_Section_II_Award_1</a>  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-22-014.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-22-014.html#_Section_II_Award_1</a>

<b>PRECISION MEDICINE (4)</b>						
97.	Kidney Precision Medicine Project (KPMP) Recruitment Sites, Kidney Tissue Atlas Coordinating Center, Tissue Interrogation Sites (U01 Clinical Trial Not Allowed), & Project Central Hub (U24 Clinical Trial Not Allowed) (NIH)	RFA-DK-20-026; 27; 28; 29	The KPMP Recruitment Sites (RS) to enroll participants with either acute kidney injury (AKI) and/or chronic kidney disease (CKD) into a longitudinal cohort study and perform protocol-based research kidney biopsies. The specific responsibilities of the Kidney Tissue Atlas Coordinating Center KTACC will be to clean, harmonize, store, and curate all de-identified KPMP data and (1) use state-of-the-art computational approaches to carry out integrative analyses, and (2) build an interactive Kidney Tissue Atlas with FAIR principles (findable, accessible, interoperable, and reusable) to promote data retrieval, exploration, discovery, and analysis by the community. The Tissue Interrogation Sites TIS FOA is for applications to analyze human kidney tissue. The Central Hub (CH) to support the KPMP cohort, collect and de-identify all existing and new clinical data and samples, and provide scientific, infrastructure, quality control, project management, and administrative support.	Letter of Intent Due: 8/23/21  Proposal Due: 9/23/21	Up to \$1.3 million per year, for up to 5 years  Dependent upon award mechanism	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-026.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-026.html#_Section_II._Award_1</a>  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-027.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-027.html#_Section_II._Award_1</a>  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-028.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-028.html#_Section_II._Award_1</a>  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-029.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-029.html#_Section_II._Award_1</a>
<b>SMALL BUSINESS DEVELOPMENT (2)</b>						
98.	Federal and State Technology (FAST) Partnership Program (SBA)	SB-OIIFT-21-001	The mission of SBA's Office of Innovation & Technology, which bears responsibility for administering the FAST Program, is to strengthen the technological competitiveness of small businesses across the country through coordination and oversight of the SBIR and STTR programs. The primary mission of the FAST program is to help underrepresented entrepreneurs successfully compete for SBIR/STTR awards. Through this FOA provides funding to organizations to execute state/regional programs that increase the number of SBIR/STTR proposals leading to an increase in the number of SBIR/STTR awards from women, socially/economically disadvantaged individuals, and small businesses in underrepresented areas - typically rural states.	Proposal Due: 6/3/21	Up to \$125,000 per year, for up to 3 years	<a href="https://www.grantsofopportunities.gov/gs/previewPublicAnnouncement.do?id=92550">https://www.grantsofopportunities.gov/gs/previewPublicAnnouncement.do?id=92550</a>

99.	PRIME-2021-01 (SBA)	SB- OCAPR- 21-001	<p align="center"><b>SMALL BUSINESS DEVELOPMENT</b></p> <p>The PRIME Act authorizes the SBA Administrator to establish a program for the purposes of: (i) providing training and technical assistance to disadvantaged entrepreneurs; (ii) providing training and capacity building assistance to microenterprise development organizations (MDOs) and programs; (iii) aiding in Research and development of best practices for microenterprise and technical assistance programs for disadvantaged entrepreneurs; and (iv) for other activities as the SBA Administrator determines.</p>	Proposal Due: 5/20/21	Up to \$250,000, for 1 year	<a href="https://www.grantsolutions.gov/gs/previewPublicAnnouncement.do?id=92516">https://www.grantsolutions.gov/gs/previewPublicAnnouncement.do?id=92516</a>
			<b>STEM EDUCATION &amp; WORKFORCE DEVELOPMENT (25)</b>			
100.	Robert Noyce Teacher Scholarship Program (NSF)	21-578	NSF invites innovative proposals that address the critical need for recruiting, preparing, and retaining highly effective elementary and secondary mathematics and science teachers and teacher leaders in high-need school districts. To achieve this goal, Noyce supports talented STEM undergraduate majors and professionals to become effective K-12 STEM teachers. It also supports experienced, exemplary K-12 STEM teachers to become teacher leaders in high-need school districts.	Proposal Due: 8/31/21	Up to \$3 million, for up to 6 years  Dependent upon award mechanism	<a href="https://www.nsf.gov/pubs/2021/nsf21578/nsf21578.htm#award_info">https://www.nsf.gov/pubs/2021/nsf21578/nsf21578.htm#award_info</a>
101.	Enhancing NIDCD's Extramural Workforce Diversity through Research Experiences (R25 Clinical Trial Not Allowed) (NIH)	PAR-21- 186	This Enhancing NIDCD's Extramural Workforce Diversity through Research Experiences R25 Program is a flexible and specialized initiative designed to foster the development of NIDCD researchers from diverse backgrounds, including from underrepresented groups, across career stages. Thus, it encourages applications from organizations that propose innovative research experiences in all NIDCD research areas. This program will focus on strategies that have been shown to affect the participation of underrepresented students at the undergraduate, predoctoral and postdoctoral level, as well as early-to-mid-career faculty in biomedical research.	Proposal Due: 5/28/21 9/24/21	Up to \$250,000 per year, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-186.html#SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PAR-21-186.html# Section II. Award 1</a>
102.	Improving Undergraduate STEM Education: Education and Human Resources (IUSE: EHR) (NSF)	21-579	The IUSE: EHR is a core NSF STEM education program that seeks to promote novel, creative, and transformative approaches to generating and using new knowledge about STEM teaching and learning to improve STEM education for undergraduate students. The program is open to application from all institutions of higher education and associated organizations. In pursuit of this goal, IUSE: EHR supports projects that seek to bring recent advances in STEM knowledge into undergraduate education, that adapt, improve, and incorporate evidence-based practices into STEM teaching and learning, and that lay the groundwork for institutional improvement in STEM education.	Proposal Due: 7/21/21	Up to \$2 million, for up to 5 years	<a href="https://www.nsf.gov/pubs/2021/nsf21579/nsf21579.htm#award_info">https://www.nsf.gov/pubs/2021/nsf21579/nsf21579.htm#award_info</a>

103.	Air Force Fiscal Year 2022 Young Investigator Research Program (DoD)	FOA-AFRL-AFOSR-2021-0006	<p><b>STEM EDUCATION &amp; WORKFORCE DEVELOPMENT</b></p> <p>Air Force Young Investigator Research Program (YIP) intends to support early in career scientists and engineers who have received Ph.D. or equivalent degrees by 1 April 2015 or later showing exceptional ability and promise for conducting basic research. The program objective is to foster creative basic research in science and engineering; enhance early career development of outstanding young investigators; and increase opportunities for the young investigator to recognize the Air Force and Space Force mission and related challenges in science and engineering.</p>	<p>White Papers Due: 5/31/21</p> <p>Proposal Due: 7/12/21</p>	Up to \$150,000 per year, for 3 years	<p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=332937">https://www.grants.gov/web/grants/view-opportunity.html?opId=332937</a></p> <p>(Full Announcement in Related Documents Tab)</p>
104.	Blueprint and BRAIN Initiative Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) Award (F99/K00 Clinical Trial Not Allowed) (NIH)	RFA-NS-21-012	<p>The purpose of the D-SPAN Award is to support a defined pathway across career stages for outstanding graduate students from diverse backgrounds, including those from groups underrepresented in biomedical and behavioral sciences. This two-phase award will facilitate completion of the doctoral dissertation and transition of talented graduate students to strong neuroscience research postdoctoral positions, and will provide career development opportunities relevant to their long-term career goal of becoming independent neuroscience researchers. FOA does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>	<p>Letter of Intent Due: 11/15/21</p> <p>Proposal Due: 12/15/21</p>	Dependent upon proposal, for up to 6 years	<p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-012.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-012.html#_Section II. Award 1</a></p>
105.	NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Independent Clinical Trial Not Allowed) (NIH)	PAR-21-234	<p>The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from backgrounds underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees and are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This FOA is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.</p>	<p>Proposal Due: 6/12/21 10/12/21</p>	Dependent upon proposal, for up to 5 years	<p><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-234.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-21-234.html#_Section II. Award 1</a></p>

106.	NIH Director's Early Independence Awards (DP5 Clinical Trial Optional) (NIH)	RFA-RM-21-018	<p><b>STEM EDUCATION &amp; WORKFORCE DEVELOPMENT</b></p> <p>The NIH Director's Early Independence Award provides an opportunity for exceptional junior scientists to accelerate their entry into an independent research career by forgoing the traditional post-doctoral training period. Though most newly graduated doctoral-level researchers would benefit from post-doctoral training, a small number of outstanding junior investigators are capable of launching directly into an independent research career. The Early Independence Award is intended for these select junior investigators who have already established a record of scientific innovation and research productivity and have demonstrated unusual scientific vision and maturity; typical post-doctoral training would unnecessarily delay their entry into independent research.</p>	<p>Letter of Intent Due: 8/3/21</p> <p>Proposal Due: 9/3/21</p>	Up to \$250,000 per year, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-21-018.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-21-018.html#_SectionII.Award1</a>
107.	Resource Center for the Support for Research Excellence (SuRE) Program (U24 - Clinical Trial Not Allowed) (NIH)	PAR-21-227	<p>The SuRE program supports research capacity building at institutions that enroll significant numbers of students from backgrounds nationally underrepresented in biomedical research (see <a href="#">NOT-OD-20-031</a>), award baccalaureate and/or graduate degrees in biomedical sciences, and receive limited NIH <a href="#">Research Project Grant</a> funding. It seeks to develop and sustain research excellence of faculty investigators and provide students with research opportunities while catalyzing enhancement of institutional research culture and enriching the research environment. The SuRE program will support investigator-initiated research in the biomedical, clinical, behavioral and social sciences that falls in the mission areas of NIH Institutes, Centers, and Offices. Research activities funded by the SuRE program require participation by students. This FOA supports a SuRE Resource Center to enable broader participation in the SuRE program nationally, thus maximizing the program's impact in developing and sustaining research excellence at eligible institutions.</p>	<p>Letter of Intent Due: 8/24/21</p> <p>Proposal Due: 9/24/21</p>	Up to \$750,000 per year, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/par-files/PAR-21-227.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/par-files/PAR-21-227.html#_SectionII.Award1</a>
108.	NIDDK Short-Term Research Experience Program to Unlock Potential (STEP-UP) (R25 Clinical Trial Not Allowed) (NIH)	RFA-DK-21-023	<p>NIDDK's STEP-UP provides funding to research institutions to provide for a national summer research experience program for both high school and undergraduate students for eight to ten weeks. STEP-UP seeks to facilitate exposure opportunities for students from diverse backgrounds, including students from groups underrepresented in biomedical research on a national basis, such as individuals from disadvantaged backgrounds, individuals from underrepresented racial and ethnic groups, and individuals with disabilities.</p>	<p>Letter of Intent Due: 8/1/21</p> <p>Proposal Due: 9/1/21</p>	Up to \$360,000 per year, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-023.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-023.html#_SectionII.Award1</a>

109.	Research Experiences for Teachers Sites in Biological Sciences (BIORETS) (NSF)	21-584	<p><b>STEM EDUCATION &amp; WORKFORCE DEVELOPMENT</b></p> <p>RETS with a focus on Biological Sciences (BIORETS) will include research projects in fields that are supported by the Directorate for Biological Sciences. BIORETS may be based in a single discipline or department or may offer interdisciplinary or multi-department research opportunities with a coherent intellectual theme. An important goal of the program is to increase the participation of underrepresented groups in biological research and those from geographically underrepresented areas in STEM. Proposals are strongly encouraged to involve members of these groups both as participants and as mentors.</p>	Proposal Due: 8/2/21	Up to \$600,000, for up to 3 years	<a href="https://www.nsf.gov/pubs/2021/nsf21584/nsf21584.htm#award_info">https://www.nsf.gov/pubs/2021/nsf21584/nsf21584.htm#award_info</a>
110.	NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional) (NIH)	RFA-HL-23-005	The purpose of the NHLBI EIA is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrate their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The EIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards.	Letter of Intent Due: 1/15/22 Proposal Due: 2/15/22	Up to \$700,000 per year, for up to 7 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-005.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-005.html#_Section II. Award 1</a>
111.	NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional) (NIH)	RFA-HL-23-004	The purpose of the NHLBI OIA is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrates their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The OIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards.	Letter of Intent Due: 1/15/22 Proposal Due: 2/15/22	Up to \$700,000 per year, for up to 7 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-004.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-004.html#_Section II. Award 1</a>
112.	Research Program Award (R35 Clinical Trial Optional) (NIH)	RFA-NS-21-020	The purpose of the NINDS RPA is to provide longer-term support and increased freedom and flexibility to Program Directors (PDs)/Principal Investigators (PIs) to allow them to redirect their time away from the administrative burden of writing and managing multiple grant applications and towards engaging in the lab. This RPA affords investigators at most career stages the opportunity to advance their long-term research goals, rigorously explore exciting research opportunities, and mentor trainees, which support and align with the mission of NINDS.	Letter of Intent Due: 6/13/21 Proposal Due: 7/13/21	Up to \$750,000 per year, for up to 8 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-020.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-020.html#_Section II. Award 1</a>

113.	Notice of Special Interest: Administrative Supplements to Promote Diversity for NINDS Alzheimer's Disease and Alzheimer's Disease-Related Dementias Awardees (NIH)	NOT-NS-21-047  PA-21-071	<p align="center"><b>STEM EDUCATION &amp; WORKFORCE DEVELOPMENT</b></p> <p>This Notice encourages eligible NINDS awardees in the Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) research community to apply for administrative supplements in response to <a href="#">PA-21-071</a>, "Research Supplements to Promote Diversity in Health-Related Research.". The NIH has a strong interest in the diversity of the NIH-funded workforce and encourages institutions to diversify their student populations by enhancing the participation of individuals from groups that are underrepresented in the biomedical, clinical, behavioral, and social sciences. Goal 1 of the <a href="#">National Plan to Address Alzheimer's Disease</a> is to prevent and effectively treat AD/ADRD by 2025. This initiative addresses the critical need to increase the number of health professionals and researchers who are trained to meet the expanding demand for cognitive impairment and dementia diagnosis, care, and research to meet Goal 1.</p>	Proposals accepted on a rolling basis	Dependent upon proposal	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-NS-21-047.html">https://grants.nih.gov/grants/guide/notice-files/NOT-NS-21-047.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-21-071.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-21-071.html#_Section II. Award 1</a>
114.	Notice of Special Interest to Encourage Eligible HEAL Initiative Awardees to Apply for Administrative Supplements to Support Career Enhancement Related to Clinical Research on Pain (Admin Supp – Clinical Trial Not Allowed) (NIH)	NOT-NS-21-048  PA-181-591	<p>For the HEAL Initiative and NIH to meet their long-term goals of providing effective non-opioid options for the treatment of pain conditions and innovative approaches for treating opioid use disorders, it will be necessary to train a new generation of clinical pain researchers. Leveraging HEAL Initiative clinical research programs to train novice researchers and investigators new to pain research in the mechanics, techniques, and best practices of clinical pain research will maximize the impact of HEAL funding for both current and future research endeavors. Increasing the number of individuals trained in high quality clinical pain research is a critical step toward ensuring the highest impact of HEAL, with studies that encompass a broad range of pain conditions and have the potential to include, address the needs of, and positively impact diverse and traditionally under-served patient populations. This supplement to existing HEAL clinical research awards is intended to allow exceptional graduate, post-doctoral or early career individuals (hereafter "candidates") to expand their clinical pain research experience and gain access to the tools and skills needed to prepare them for a career in clinical pain research.</p>	Proposal Due: 6/1/21	Up to \$50,000 per years, for up to 2 years	<a href="https://grants.nih.gov/grants/guide/notice-files/not-ns-21-048.html">https://grants.nih.gov/grants/guide/notice-files/not-ns-21-048.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-591.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/pa-18-591.html#_Section II. Award 1</a>

115.	HEAL Initiative: Notice of Special Interest (NOSI): Limited Competition to Support Mentorship of Junior Investigators (NIH)	NOT-NS-21-026 PA-20-193	<p align="center"><b>STEM EDUCATION &amp; WORKFORCE DEVELOPMENT</b></p> <p>This NOSI provides an opportunity for researchers funded by the Helping to End Addiction Long-Term (HEAL) initiative to devote more time to patient-oriented research and mentoring. For the purposes of the K24 award, patient-oriented research is defined as research conducted with human subjects for which an investigator (or colleague) directly interacts with human subjects. This area of research includes: 1) therapeutic interventions, and 2) clinical trials. NIH ICs participating in HEAL are issuing this notice to highlight their interest in receiving applications from HEAL investigators for a K24 award. Use PA-20-193 to apply</p>	Proposal Due: 6/14/21	Up to \$300,000, for up to 3 years	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-NS-21-026.html?utm_medium=email&amp;utm_source=govdelivery">https://grants.nih.gov/grants/guide/notice-files/NOT-NS-21-026.html?utm_medium=email&amp;utm_source=govdelivery</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-193.html#_SectionII.Award2">https://grants.nih.gov/grants/guide/pa-files/PA-20-193.html#_SectionII.Award2</a>
116.	Notice of Special Interest: NIH Research Project Grant (R01) Applications from Individuals from Diverse Backgrounds, Including Under-Represented Minorities (NIH)	NOT-NS-21-049 PA-20-183; 184; 185	<p>NINDS seeks to promote diversity in all of its research programs and to increase the participation of underrepresented groups. As the US population becomes increasingly diverse, reflection of that diversity among the biomedical research workforce is vital to our science enterprise and the NIH research mission (See <a href="#">NOT-OD-20-031</a>). NIH is committed to implementing approaches to address the funding gap for researchers from diverse backgrounds and “committed to instituting new ways to support diversity, equity, and inclusion, and identifying and dismantling any policies and practices that may harm our workforce and our science”. This NOSI utilizes the NIH parent R01 announcement to encourage Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) from diverse backgrounds to conduct and contribute to the <a href="#">research areas</a> of the NINDS. The long-term goal of this effort is to enhance diversity in the biomedical research workforce.</p>	Proposal Due: 6/5/21 10/5/21	Dependent upon proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-NS-21-049.html">https://grants.nih.gov/grants/guide/notice-files/NOT-NS-21-049.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-183.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-20-183.html#_SectionII.Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-184.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-20-184.html#_SectionII.Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html#_SectionII.Award1</a>

117.	Defense Established Program to Stimulate Competitive Research (DEPSCoR) – Research Collaboration (RC) & Capacity Building (CB) (DoD)	FOA-AFRL-AFOSR-2021-0007; 0008	<p><b>STEM EDUCATION &amp; WORKFORCE DEVELOPMENT</b></p> <p>DEPSCoR's objectives are to: (1) increase the number of university researchers in eligible States/Territories capable of performing S&amp;E research responsive to the needs of the DoD; and (2) enhance the capabilities of institutions of higher education (IHE) in eligible States/Territories to develop, plan, and execute science and engineering (S&amp;E) research that is relevant to the mission of the DoD, and competitive under the peer-review systems used for awarding Federal research assistance; (3) increase the probability of long-term growth in the competitively awarded financial assistance that IHE in eligible States receive from the Federal Government for S&amp;E research. Consistent with these long-term objectives of building research infrastructure, the DoD also intends to competitively make multiyear awards for capacity building in IHEs with research areas relevant to the DoD's mission and which are important to national security.</p>	<p>White Paper Due: 9/20/21</p> <p>Proposal Due: 2/22/22</p>	<p>Up to \$500,000 per year, for up to 2 years</p> <p>Dependent upon award mechanism</p>	<p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=333421">https://www.grants.gov/web/grants/view-opportunity.html?opId=333421</a></p> <p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=333435">https://www.grants.gov/web/grants/view-opportunity.html?opId=333435</a></p> <p>(Full Announcement in Related Documents Tab)</p>
<b>SUBSTANCE ABUSE (33)</b>						
118.	Pre-Announcement Improving Care for the Substance-exposed Mother-Infant dyad – Health Information Technology Tool Development (HHS/OASH)	WH-AST-21-002	<p>This initiative will support comprehensive logistical, data/performance measures and technical support to develop a prototype of the proposed NAS clinical IT tracking tool. The goals of this initiative are specifically to: 1) Partner with pediatric health institutions in various geographic and demographic regions experiencing a higher incidence of NAS and maternal OUD, 2) work with the expertise of organizational EMR and IT teams to identify essential site-based resources (including IT developer, systems administrator, information systems security officer, data scientist) in developing the format for a prototype, 3) pilot the IT prototype in an outpatient clinical setting serving a high volume of opioid-exposed infants and mothers, &amp; 4) finalize an open-source, interoperable clinical IT tracking tool</p>	<p>Estimated Post Date: 5/15/21</p> <p>Estimated Proposal Due Date: 7/15/21</p>	<p>Up to \$450,000, per award</p>	<p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=332917">https://www.grants.gov/web/grants/view-opportunity.html?opId=332917</a></p>
119.	Mobile Health Solutions to rectify digital inequality in communities affected by drug addiction (NIH)	RFA-DA-22-001	<p>This FOA, invites eligible United States small business concerns to submit SBIR grant applications to develop mobile health technologies, including wearables and other digital health enabled technologies, to address existing digital inequalities affecting underserved and vulnerable populations suffering from Substance Use Disorders (SUD). Specific activities to be proposed will vary. For applications proposing FDA-regulated devices, applicants are encouraged to include activities that lead to engagement with the FDA, in order to confirm the appropriate regulatory path with respect to the proposed intended use.</p>	<p>Estimated Post Date: 7/13/21</p> <p>Estimated Proposal Due Date: 8/13/21</p>	<p>Up to \$259,613 for up to 6 months (Phase I) &amp; Up to \$1.7 million for up to 2 years (Phase II)</p>	<p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-001.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-001.html#_Section_II._Award_1</a></p>

120.	Pre-Announcement Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD) Research Project, Administrative Core, Diagnostic-Telemedicine Core, Developmental Project & Coordination Core (NIH)	NOT-AA-21-020; 021; 022; 023; 024	<p style="text-align: center;"><b>SUBSTANCE ABUSE</b></p> <p>NIAAA intends to publish a FOA to solicit applications from current awardees and new applicants to continue the previously funded “Collaborative Initiative on Fetal Alcohol Spectrum Disorders” (CIFASD). Responsive applications are expected 1) to address urgent and important unmet needs in the fetal alcohol spectrum disorders (FASD) field in the areas of diagnosis/case identification, intervention, basic and mechanistic studies, and prevention; 2) to use integrated and multiple cohorts of individuals with FASD. Accompanying FOAs will fund administrative, diagnostic and coordination cores to support research endeavors under CIFASD.</p>	<p>Estimated Post Date: 5/15/21</p> <p>Estimated Proposal Due Date: 8/15/21</p>	Dependent upon proposal	<p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=333300">https://www.grants.gov/web/grants/view-opportunity.html?opId=333300</a></p> <p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=333302">https://www.grants.gov/web/grants/view-opportunity.html?opId=333302</a></p> <p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=333303">https://www.grants.gov/web/grants/view-opportunity.html?opId=333303</a></p> <p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=333325">https://www.grants.gov/web/grants/view-opportunity.html?opId=333325</a></p> <p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=333324">https://www.grants.gov/web/grants/view-opportunity.html?opId=333324</a></p>
121.	Notice of Special Interest: Women and Sex/Gender Differences in Drug and Alcohol Abuse, Dependence (NIH)	NOT-DA-21-012  PAR-20-146; 183; 184; 194; 195; 196	The purpose of this Notice is to inform potential applicants of the NIDA special interest in grant applications to conduct rigorous basic, translational and/or clinical research to: (1) advance identification of sex and/or gender differences in risk for substance use disorders or the response or medical consequences of alcohol or substance misuse to uncover the mechanisms of those differences, and to conduct translational research on those differences, and (2) advance research specific to women or highly relevant to women. Both preclinical and clinical studies are sought across all areas of drug and alcohol research. Multiple FOAs can be used to apply for this NOSI.	Proposal Due: 6/5/21 6/16/21 10/5/21 10/16/21	Dependent upon proposal, for up to 5 years  Dependent upon award mechanism	<p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-DA-21-012.html">https://grants.nih.gov/grants/guide/notice-files/NOT-DA-21-012.html</a></p> <p><a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-146.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-146.html#_Section_II_Award_1</a></p>

122.	Notice of Special Interest: Leveraging Longitudinal Studies in Animal Models to Identify Neural Mechanisms of Vulnerability and Resilience to Substance Use Disorder (NIH)	NOT-DA-21-003  PA-20-185; 195  PAR-18-714  PAR-19-134; 310	<p style="text-align: center;"><b>SUBSTANCE ABUSE</b></p> <p>NIDA seeks to stimulate research in non-human species aimed at modeling environmental and/or biological risk factors for SUD to elucidate neural and cognitive developmental mechanisms that may mediate, moderate, or predict the effects of these factors on subsequent emergence of SUD-related behaviors. Use of longitudinal designs and developmental-stage-appropriate paradigms are strongly encouraged. Research areas of interest for this announcement include, but are not limited to, the following:</p> <ul style="list-style-type: none"> <li>• Identification of neurobiological substrates of risk and resilience and how they are determined by early-life experience (e.g. resource scarcity, parental behavior) or exposures (drugs, toxins, nutrition)</li> <li>• Neuromechanistic studies of sensitive or critical periods across development that may impact substance use, seeking and SUD-relevant behavioral abnormalities</li> <li>• Modeling of interactions between genetic and environmental factors across development on SUD-relevant neurocognitive, behavioral and/or psychophysiological phenotypes in adolescence and adulthood</li> <li>• Data- or model-driven analysis of complex behavior captured in naturalistic settings across stages of development in the context of SUD risk and/or resilience</li> </ul>	Proposal Due: 6/5/21 6/16/21 10/5/21 10/16/21	Dependent upon proposal, for up to 5 years  Dependent upon award mechanism	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-DA-21-003.html">https://grants.nih.gov/grants/guide/notice-files/NOT-DA-21-003.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html#_Section II. Award 1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-195.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-195.html#_Section II. Award 1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/par-18-714.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/par-18-714.html#_Section II. Award 1</a>
123.	Notice of Special Interest: Leveraging transformative connectome resources in model organisms to elucidate the neurobiology of substance use disorders (NIH)	NOT-DA-21-006  PA-20-184; 185; 195; 200; 272  PAR-18-437  RFA-DA-22-006	The purpose of this notice is to encourage research project submissions that leverage whole-brain or large connectome resources in genetically tractable model organisms to investigate the role of distributed neuronal circuits in behaviors relevant to substance use disorders (SUD). Historically, animal research in the substance use field has relied mainly on rats and non-human primates to “model” the effects of drugs on human behavior. Expansion into the use of mice, because they are genetically tractable, together with the emergence of genetic tools that target cells with specificity, revolutionized the field by allowing for more precise monitoring and manipulation of brain circuits. However, the field has not taken full advantage of the many other genetically tractable non-mammalian organisms, such as drosophila, zebrafish and C.elegans. The modest size of their nervous system and transformative connectome resources generated in recent years have positioned these model systems as unparalleled choices for the systematic investigation of distributed neuronal circuits underlying behavioral repertoires relevant to substance use.	Proposal Due: 6/5/21 6/16/21 10/5/21 10/16/21	Dependent upon proposal, for up to 5 years  Dependent upon award mechanism	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-DA-21-006.html">https://grants.nih.gov/grants/guide/notice-files/NOT-DA-21-006.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-184.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-184.html#_Section II. Award 1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html#_Section II. Award 1</a>

124.	Notice of Special Interest: Public Policy Effects on Alcohol-, Cannabis-, Tobacco-, and Other Drug-Related Behaviors and Outcomes (NIH)	NOT-AA-21-028  PA-20-183; 185; 194; 195; 200	<b>SUBSTANCE ABUSE</b>  The purpose of the Notice is to advance understanding of how public policy may serve as a tool for improving public health and welfare through its effects on behaviors and outcomes pertaining to alcohol and other drugs. Research projects that may be supported include, but are not necessarily limited to: causal analyses of the effects of one or multiple public policies; evaluations of the effectiveness of specific public policies as tools for improving public health through their effects on alcohol-, cannabis-, tobacco-, and other substance-related behaviors and outcomes; studies of disparities in policy effects and the role of policy in exacerbating or potentially reducing health disparities; and research to advance methods and measurement used in studying relationships between public policies and alcohol-, cannabis-, tobacco-, and other substance-related behaviors and outcomes. Multiple FOAs can be used to apply to this NOSI.	Proposal Due: 6/5/21 6/16/21 10/5/21 10/16/21	Dependent upon proposal, for up to 5 years  Dependent upon award mechanism	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AA-21-028.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AA-21-028.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-183.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-183.html#_Section II. Award 1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html#_Section II. Award 1</a>
			<b>VACCINES (1)</b>			
125.	Pre-Announcement Vaccine Confidence Collaboration (HHS/OASH)	NV-VSR-21-001	Vaccines are among the most effective public health interventions available, behind only access to clean water in terms of reducing the burden of infectious diseases. An essential pillar of success for a national vaccine program is maintaining high rates of immunity in communities. To reach the necessary number of vaccinated individuals within a population for community immunity, a high level of public trust in the immunization systems, i.e., vaccine confidence, is needed. The initiative will look to the work of local communities and their partnerships with immunization “champions” to identify, plan, implement, and evaluate evidence-based practices.	Estimated Proposal Due Date: 6/30/21	Up to \$125,000, per award	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=332874">https://www.grants.gov/web/grants/view-opportunity.html?opId=332874</a>
			<b>WOMEN’S HEALTH (8)</b>			
126.	PCORI Funding Announcement: Improving Postpartum Maternal Outcomes for Populations Experiencing Disparities (PCORI)	N/A	This FOA seeks to fund large randomized controlled trials and/or well-designed observational studies comparing multicomponent strategies to improve early detection of, and timely care for, complications up to six weeks postpartum for groups more often underserved or experiencing the greatest disparities in health outcomes. PCORI is particularly interested in comparative effectiveness of different tailored approaches to intervention strategies. Applicants should consider the following outcome categories: maternal mortality and morbidity; healthcare utilization; condition-specific outcomes; and patient experience, satisfaction, and engagement.	Letter of Intent Due: 6/1/21  Proposal Due: 8/31/21	Up to \$15 million, for up to 5 years	<a href="https://www.pcori.org/sites/default/files/PCORI-2021-Cycle-2-MMM-PFA.pdf">https://www.pcori.org/sites/default/files/PCORI-2021-Cycle-2-MMM-PFA.pdf</a>

127.	Nonsurgical Options for Women with Urinary Incontinence -- Cycle 2 2021 (PCORI)	N/A	<p style="text-align: center;"><b>WOMEN'S HEALTH</b></p> <p>This FOA seeks to fund high-quality, comparative effectiveness research projects that focus on efficacious interventions for nonpregnant women with stress, urge, or mixed urinary incontinence (UI), addressing high-priority patient- and stakeholder-guided research questions. Although there is good evidence for the efficacy of many nonsurgical interventions for UI*, evidence gaps remain, particularly related to direct comparisons of the options. PCORI will accept applications that propose rigorous randomized controlled trials or observational, prospective cohort studies. Applicants can propose to compare two or more of the nonsurgical treatment options for UI, including pharmacological, behavioral, lifestyle, and other nonpharmacological options.</p>	<p>Letter of Intent Due: 6/1/21</p> <p>Proposal Due: 8/31/21</p>	<p>Up to \$5 million, for up to 5 years</p>	<p><a href="https://www.pcori.org/sites/default/files/PCORI-2021-Cycle-2-UI-PFA.pdf">https://www.pcori.org/sites/default/files/PCORI-2021-Cycle-2-UI-PFA.pdf</a></p>
128.	Notice of Special Interest: Reproductive Health, Pregnancy, and Parenting among Women with Disabilities (NIH)	NOT-HD-21-025 PA-20-183; 185; 200; 221; 223	<p>The objectives of this NOSI are to advance knowledge of the gynecologic care, preconception health, pregnancy, and parenting experiences of women with disabilities (WWD); to reduce barriers to inclusion in meaningful reproductive health, pregnancy, and parenting experiences among WWD; and to improve outcomes in reproductive health, pregnancy, and parenting for WWD and their children. This NOSI encourages research aimed at elucidating multi-level factors and establishing a strong evidence base for interventions and clinical practice guidelines that will support healthcare access and inclusion, relevant assistive device and technology development, and environmental modifications in this scientific area.</p>	<p>Proposal Due: 6/5/21 10/5/21</p>	<p>Dependent upon proposal, for up to 5 years</p>	<p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-HD-21-025.html">https://grants.nih.gov/grants/guide/notice-files/NOT-HD-21-025.html</a></p> <p><a href="https://grants.nih.gov/grants/guide/pa-files/pa-20-183.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/pa-20-183.html#_Section II. Award 1</a></p> <p><a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html#_Section II. Award 1</a></p>

OTHER (4)						
129.	Military-Civilian National Disaster Medical System (NDMS) Interoperability Study (MCNIS) Pilot Program (DoD/MTEC)	MTEC-21-11-NDMS	This RPP is focused on the development and implementation of the National Disaster Medical System (NDMS) Pilot Program. The Pilot is a congressionally required prototype, which will serve as a proof of concept to inform nationwide changes to the existing NDMS. The purpose of the Pilot is to strengthen interoperable partnerships of the NDMS to care for our Nation's combat casualties by increasing medical surge capabilities and capacities at five regional sites. This will be achieved through a collaborative network of federal and civilian NDMS partners. The current Pilot Phase I activities will be transitioning to Phase II. This RPP is specifically focused on the activities associated with Phase II, which include conducting further NDMS studies, systematically implementing recommended changes, measuring intervention outcomes, and iteratively making improvements to optimize Pilot performance at the five sites. The information generated in Phase II will inform system-wide changes for nationwide implementation in Phase III.	Enhanced White Paper Due: 5/28/21	Dependent upon proposal, for up to 1 year	<a href="https://www.mtec-sc.org/wp-content/uploads/2021/04/21-11-NDMS-RPP.pdf">https://www.mtec-sc.org/wp-content/uploads/2021/04/21-11-NDMS-RPP.pdf</a>
130.	Biomarker Research to Support Fertility Regulation Development by Small Business (R43 Clinical Trial Optional) (NIH)	RFA-HD-22-018	Nearly half of all pregnancies in the United States are unintended. Pursuant to the critical need for new non-hormonal contraceptives for men and women, including those that incorporate an anti-infective property, is the development of biomarkers that demonstrate the contraceptive product's efficacy (e.g., pharmacodynamic, pharmacokinetic, drug-target interaction) in a clinical setting. This FOA invites SBIR applications to support and facilitate the development of new and/or improved clinical biomarkers and companion biomarker diagnostics to support the clinical development of non-hormonal contraceptive product(s).	Letter of Intent Due: 6/29/21  Proposal Due: 7/29/21	Up to \$259,613, for 1 year	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-22-018.html#_Section_I._Funding">https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-22-018.html#_Section I. Funding</a>
131.	Countermeasures Against Chemical Threats (CounterACT) Early-stage Investigator Research Award (R21 Clinical Trial Not Allowed) (NIH)	PAR-21-209	The purpose of this FOA is to recruit Early Stage Investigators (ESI) to pursue research programs of interest to NIH Chemical Countermeasures Research Program (CCRP) under the CounterACT grant/cooperative agreement program. ESI CounterACT R21 projects may be exploratory, applied, proof of principle, or high risk-high impact research to discover safe and effective therapeutics to mitigate toxicities resulting from exposures to highly toxic chemicals. A distinct feature for this FOA is that no preliminary data are required, expected, or encouraged. However, if available, minimal preliminary data are allowed.	Letter of Intent Due: 6/27/21  Proposal Due: 7/27/21	Up to \$400,000, for up to 3 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-209.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-21-209.html#_Section II. Award 1</a>

132.	Human Milk as a Biological System (R01 Clinical Trial Optional) (NIH)	RFA-HD-22-020	<p style="text-align: center;"><b>OTHER</b></p> <p>The purpose of this FOA is to invite grant applications that address priority gaps in our understanding of human milk as a biological system and that expand our understanding of the myriad factors influencing the composition and function of human milk using a systems biology approach. Research topics responsive to this FOA include, but are not limited to, the following:</p> <ul style="list-style-type: none"> <li>• Maternal factors influencing the systems biology of breastmilk</li> <li>• The components of human milk and defining their roles</li> <li>• Infant factors affecting the systems biology of human milk</li> <li>• New modeling techniques that allow investigators to model human milk as a system and interrogate the system</li> </ul>	<p>Letter of Intent Due: 10/29/21</p> <p>Proposal Due: 11/29/21</p>	<p>Up to \$499,999 per year, for up to 5 years</p>	<p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-22-020.html#_SectionII.Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-22-020.html#_SectionII.Award_1</a></p>
------	---	---------------	--	---	--	--